Subjects	O
will	O
be	O
excluded	O
from	O
study	O
enrollment	O
if	O
they	O
meet	O
any	O
of	O
the	O
following	O
criteria	O

Exclusion	O
criteria	O

[	O
42	O
]	O
Have	O
received	O
plasmapheresis	B-treatment
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
.	O

[	O
43	O
]	O
Have	O
or	O
had	O
a	B-problem
herpes	I-problem
zoster	I-problem
or	O
any	B-problem
other	I-problem
clinically	I-problem
apparent	I-problem
varicella	I-problem
-	I-problem
zoster	I-problem
virus	I-problem
infection	I-problem
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
first	I-TEMPORAL
admission	I-TEMPORAL
to	I-TEMPORAL
the	I-TEMPORAL
CRU	I-TEMPORAL
.	O

If	O
the	O
previous	O
IP	O
has	O
a	O
long	O
half	O
-	O
life	O
,	O
3	O
months	O
or	O
5	O
half	O
-	O
lives	O
,	O
whichever	O
is	O
longer	O
,	O
should	O
have	O
passed	O
.	O

[	O
44	O
]	O
Have	O
donated	O
>	B-VALUE
450	I-VALUE
mL	I-VALUE
of	O
blood	O
within	B-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL
(	I-TEMPORAL
Visit	I-TEMPORAL
1	I-TEMPORAL
)	I-TEMPORAL
,	O
or	O
intend	O
to	O
donate	B-problem
blood	I-problem
during	B-TEMPORAL
the	I-TEMPORAL
course	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
.	I-TEMPORAL

8	O
.	O
2	O
.	O

If	O
the	B-test
repeat	I-test
test	I-test
is	O
indeterminate	B-VALUE
,	O
the	O
patient	O
will	O
be	O
excluded	O
from	O
the	O
study	O
.	O

[	O
32	O
]	O
Have	O
uncontrolled	B-problem
arterial	I-problem
hypertension	I-problem
characterized	O
by	O
a	B-test
systolic	I-test
blood	I-test
pressure	I-test
(	I-test
BP	I-test
)	I-test
>	B-VALUE
160	I-VALUE
mmHg	I-VALUE
or	O
diastolic	B-test
BP	I-test
>	B-VALUE
100	I-VALUE
mmHg	I-VALUE
.	O

[	O
33	O
]	O
have	O
clinically	B-problem
significant	I-problem
multiple	I-problem
or	I-problem
severe	I-problem
drug	I-problem
allergies	I-problem
,	O
or	O
intolerance	B-problem
to	I-problem
topical	I-problem
corticosteroids	I-problem
,	I-problem
or	O
severe	B-problem
post	I-problem
treatment	I-problem
hypersensitivity	I-problem
reactions	I-problem
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
erythema	B-problem
multiforme	I-problem
major	I-problem
,	O
linear	B-problem
immunoglobulin	I-problem
A	I-problem
dermatosis	I-problem
,	O
toxic	B-problem
epidermal	I-problem
necrolysis	I-problem
,	O
or	O
exfoliative	B-problem
dermatitis	I-problem
)	O

[	O
19	O
]	O
show	O
evidence	O
of	O
human	B-problem
immunodeficiency	I-problem
virus	I-problem
(	I-problem
HIV	I-problem
)	I-problem
infection	I-problem
and	O
or	O
positive	B-VALUE
human	B-test
HIV	I-test
antibodies	I-test

[	O
48	O
]	O
Show	O
evidence	O
of	O
human	B-problem
immunodeficiency	I-problem
virus	I-problem
(	I-problem
HIV	I-problem
)	I-problem
infection	I-problem
and	O
or	O
positive	B-VALUE
human	B-test
HIV	I-test
antibodies	I-test
.	O

[	O
48	O
]	O
Have	O
suicidal	B-problem
ideation	I-problem
within	B-TEMPORAL
1	I-TEMPORAL
month	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
or	O
suicide	B-problem
-	I-problem
related	I-problem
behaviors	I-problem
(	O
actual	B-problem
attempt	I-problem
,	O
interrupted	B-problem
attempt	I-problem
,	O
aborted	B-problem
attempt	I-problem
,	O
preparatory	B-problem
act	I-problem
or	I-problem
behavior	I-problem
)	O
within	B-TEMPORAL
3	I-TEMPORAL
months	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
on	O
the	O
basis	O
of	O
the	O
Columbia	O
Suicide	O
Self	O
-	O
Reported	O
Scale	O
(	O
C	O
-	O
SSRS	O
)	O
.	O

[	O
33	O
]	O
have	O
hepatitis	B-problem
C	I-problem
or	O
test	O
positive	B-VALUE
hepatitis	B-test
C	I-test
virus	I-test
at	O
screening	O
,	O
defined	O
as	O
positive	B-VALUE
result	O
for	O
hepatitis	B-test
C	I-test
antibody	I-test
and	O
positive	B-VALUE
confirmatory	B-test
PCR	I-test
test	I-test
for	I-test
hepatitis	I-test
C	I-test
virus	I-test

Patients	O
will	O
be	O
excluded	O
from	O
study	O
enrollment	O
if	O
they	O
meet	O
any	O
of	O
the	O
following	O
criteria	O

[	O
2	O
]	O
are	O
first	O
-	O
generation	O
Japanese	O
or	O
are	O
Caucasian	O
.	O

[	O
15	O
]	O
have	O
an	O
abnormality	B-VALUE
in	O
the	B-test
12	I-test
-	I-test
lead	I-test
ECG	I-test
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
increases	O
the	O
risks	O
associated	O
with	O
participating	O
in	O
the	O
study	O

Visit	O
2	O
)	O
,	O
or	O
are	O
clinically	O
judged	O
by	O
the	O
investigator	O
to	O
be	O
at	O
risk	O
for	O
suicide	O

[	O
9	O
]	O
are	O
investigative	O
site	O
personnel	O
directly	O
affiliated	O
with	O
this	O
study	O
and	O
their	O
immediate	O
families	O
.	O

[	O
39	O
]	O
have	O
a	O
positive	B-VALUE
test	O
for	O
HBV	B-test
,	O
HCV	B-test
,	O
or	O
HIV	B-test
infection	I-test
a	O
have	O
HBV	B-problem
infection	I-problem
,	O
defined	O
as	O
o	O
positive	B-VALUE
for	O
hepatitis	B-test
B	I-test
surface	I-test
antigen	I-test
(	I-test
HBsAg	I-test
)	I-test
,	O
or	O
(	B-test
DNA	I-test
)	I-test
Note	O
Patients	O
who	O
are	O
HBcAb	B-test
-	O
positive	B-VALUE
and	O
HBV	B-test
DNA	I-test
-	O
negative	B-VALUE
may	O
be	O
enrolled	O
in	O
the	O
study	O
.	O

At	O
screening	O
(	O
Visit	O
1	O
)	O
,	O
have	O
alkaline	B-test
phosphatase	I-test
(	I-test
ALP	I-test
)	I-test
>	B-VALUE
3xULN	I-VALUE
or	O
ALP	B-test
>	B-VALUE
2	I-VALUE
.	I-VALUE
5xULN	I-VALUE
and	O
total	B-test
bilirubin	I-test
>	B-VALUE
2xULN	I-VALUE

Aspartate	B-test
aminotransferase	I-test
(	I-test
AST	I-test
)	I-test
or	O
alanine	B-test
aminotransferase	I-test
(	I-test
ALT	I-test
)	I-test
>	B-VALUE
2	I-VALUE
.	I-VALUE
5	I-VALUE
times	I-VALUE
the	I-VALUE
upper	I-VALUE
limit	I-VALUE
of	I-VALUE
normal	I-VALUE
(	I-VALUE
ULN	I-VALUE
)	I-VALUE

[	O
23	O
]	O
have	O
used	O
or	O
intend	O
to	O
use	O
over	B-treatment
-	I-treatment
the	I-treatment
-	I-treatment
counter	I-treatment
or	I-treatment
prescription	I-treatment
medication	I-treatment
,	I-treatment
including	O
herbal	B-treatment
medications	I-treatment
,	I-treatment
within	B-TEMPORAL
14	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
planned	I-TEMPORAL
dosing	I-TEMPORAL

[	O
13	O
]	O
have	O
previously	O
completed	O
or	O
withdrawn	O
from	O
this	O
study	O
or	O
any	O
other	O
study	O
investigating	O
LY3090106	O
,	O
and	O
have	O
previously	O
received	O
the	O
IP	O

This	O
test	O
may	O
not	O
be	O
suitable	O
if	O
previous	O
treatment	O
(	O
s	O
)	O
produce	O
significant	O
immunosuppression	O
.	O

Exclusion	O
Criteria	O

[	O
10	O
]	O
are	O
willing	O
and	O
able	O
to	O
complete	O
the	O
scheduled	O
study	O
assessments	O
,	O
including	O
endoscopy	B-test

[	O
37g	O
]	O
serum	B-test
creatinine	I-test
>	B-VALUE
2	I-VALUE
.	I-VALUE
0	I-VALUE
mg	I-VALUE
dL	I-VALUE
.	O
(	O
Note	O
The	O
AST	B-test
and	O
ALT	B-test
may	O
be	O
repeated	O
once	B-TEMPORAL
within	I-TEMPORAL
a	I-TEMPORAL
week	I-TEMPORAL
if	O
the	O
initial	O
response	O
exceeds	O
this	O
limit	O
,	O
and	O
the	O
repeat	O
value	O
may	O
be	O
accepted	O
if	O
it	O
meets	O
this	O
criterion	O
.	O

[	O
12	O
]	O
have	O
previously	O
completed	O
or	O
withdrawn	O
from	O
this	O
study	O
or	O
any	O
other	O
study	O
investigating	O
LY3074828	O
,	O
and	O
have	O
previously	O
received	O
the	O
investigational	O
product	O

[	O
19	O
]	O
show	O
evidence	O
of	O
human	B-problem
immunodeficiency	I-problem
virus	I-problem
(	I-problem
HIV	I-problem
)	I-problem
infection	I-problem
and	O
or	O
positive	B-VALUE
human	O
HIV	B-test
antibodies	I-test

[	O
17	O
]	O
Have	O
donated	O
more	B-VALUE
than	I-VALUE
500	I-VALUE
mL	I-VALUE
of	O
blood	O
within	B-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
,	O
or	O
intend	O
to	O
donate	B-problem
blood	I-problem
during	B-TEMPORAL
the	I-TEMPORAL
course	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
.	O

a	O
.	O

[	O
29	O
]	O
Have	O
evidence	O
of	O
human	B-problem
immunodeficiency	I-problem
virus	I-problem
infection	I-problem
and	O
or	O
positive	B-VALUE
human	B-test
immunodeficiency	I-test
virus	I-test
antibodies	I-test
.	I-test

[	O
2	O
]	O
Are	O
18	O
years	O
or	O
older	O
at	O
the	O
time	O
of	O
screening	O
.	O

Investigators	O
should	O
review	O
the	O
vaccination	O
status	O
of	O
their	O
patients	O
and	O
follow	O
the	O
local	O
guidelines	O
for	O
vaccination	O
of	O
those	O
18	O
years	O
of	O
age	O
with	O
nonlive	O
vaccines	O
intended	O
to	O
prevent	O
infectious	O
disease	O
prior	O
to	O
entering	O
patients	O
into	O
the	O
study	O
.	O

[	O
6	O
]	O
Have	O
a	O
positive	B-VALUE
ANA	B-test
(	I-test
HEp	I-test
-	I-test
2	I-test
ANA	I-test
titer	I-test
1	I-test
80	I-test
)	I-test
and	O
or	O
a	O
positive	B-VALUE
anti	B-test
-	I-test
dsDNA	I-test
(	I-test
30	I-test
IU	I-test
)	I-test
as	O
assessed	O
by	O
a	O
central	O
laboratory	O
at	O
screening	O
.	O

[	O
32	O
]	O
have	O
received	O
live	B-treatment
vaccine	I-treatment
(	I-treatment
s	I-treatment
)	I-treatment
within	B-TEMPORAL
1	I-TEMPORAL
month	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
or	O
intend	O
to	O
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL

If	O
any	B-test
of	I-test
the	I-test
HB	I-test
tests	I-test
have	O
an	B-VALUE
indeterminate	I-VALUE
result	I-VALUE
,	O
confirmatory	B-test
testing	I-test
will	O
be	O
performed	O
by	O
an	O
alternate	O
method	O
.	O

[	O
1a	O
]	O
male	O
subjects	O
agree	O
to	O
use	O
an	O
effective	O
method	O
of	O
contraception	B-treatment
for	O
the	B-TEMPORAL
duration	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
and	O
12	B-TEMPORAL
weeks	I-TEMPORAL
following	I-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
dose	I-TEMPORAL
of	I-TEMPORAL
investigational	I-TEMPORAL
product	I-TEMPORAL
(	I-TEMPORAL
IP	I-TEMPORAL
)	I-TEMPORAL

Individuals	O
who	O
do	O
not	O
meet	O
the	O
criteria	O
for	O
participation	O
in	O
this	O
study	O
(	O
screen	O
failure	O
)	O
may	O
be	O
rescreened	O
in	O
the	O
following	O
circumstances	O
Patients	O
who	O
test	O
positive	O
for	O
latent	O
TB	O
at	O
screening	O
may	O
be	O
rescreened	O
following	O
appropriate	O
treatment	O
as	O
described	O
in	O
Section	O
8	O
.	O
2	O
.	O
2	O
.	O
2	O
patients	O
who	O
do	O
not	O
qualify	O
at	O
screening	O
under	O
Exclusion	O
Criteria	O

[	O
20	O
]	O
show	O
evidence	O
of	O
hepatitis	B-problem
C	I-problem
and	O
or	O
positive	B-VALUE
hepatitis	B-test
C	I-test
antibody	I-test

Note	O

[	O
1	O
]	O
are	O
overtly	O
healthy	O
males	O
or	O
females	O
,	O
as	O
determined	O
by	O
medical	O
history	O
and	O
physical	O
examination	O
.	O

in	O
the	O
opinion	O
of	O
the	O
investigator	O
or	O
sponsor	O
,	O
are	O
unsuitable	O
for	O
inclusion	O
in	O
the	O
study	O

Immediate	O
family	O
is	O
defined	O
as	O
a	O
spouse	O
,	O
parent	O
,	O
child	O
,	O
or	O
sibling	O
,	O
whether	O
biological	O
or	O
legally	O
adopted	O

8	O
.	O
1	O
.	O
1	O
.	O

At	O
screening	O
(	O
Visit	O
1	O
)	O
,	O
have	O
clinical	B-test
laboratory	I-test
test	I-test
results	O
that	O
are	O
outside	B-VALUE
the	I-VALUE
normal	I-VALUE
reference	I-VALUE
range	I-VALUE
for	O
the	O
population	O
and	O
are	O
considered	O
clinically	O
signific	O
ant	O
,	O
per	O
investigator	O
assessment	O

[	O
36	O
]	O
have	O
received	O
treatment	B-treatment
with	I-treatment
biologic	I-treatment
agents	I-treatment
(	O
such	O
as	O
monoclonal	B-treatment
antibodies	I-treatment
,	I-treatment
including	O
marketed	O
drugs	O
)	O
within	B-TEMPORAL
3	I-TEMPORAL
months	I-TEMPORAL
or	I-TEMPORAL
5	I-TEMPORAL
half	I-TEMPORAL
-	I-TEMPORAL
lives	I-TEMPORAL
(	I-TEMPORAL
whichever	I-TEMPORAL
is	I-TEMPORAL
longer	I-TEMPORAL
)	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
dosing	I-TEMPORAL
.	O

[	O
35	O
]	O
Had	O
a	B-problem
serious	I-problem
infection	I-problem
(	O
for	O
example	O
,	O
pneumonia	B-problem
,	O
cellulitis	B-problem
)	O
,	O
have	O
been	O
hospitalized	B-problem
,	O
or	O
have	O
received	O
intravenous	B-treatment
(	I-treatment
IV	I-treatment
)	I-treatment
antibiotics	I-treatment
for	O
an	O
infection	O
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
,	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
or	O
had	O
a	B-problem
serious	I-problem
bone	I-problem
or	I-problem
joint	I-problem
infection	I-problem
within	B-TEMPORAL
24	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
or	O
have	O
ever	O
had	O
an	B-problem
infection	I-problem
of	I-problem
an	I-problem
artificial	I-problem
joint	I-problem
or	O
are	O
immunocompromised	B-problem
to	O
an	O
extent	O
such	O
that	O
participation	O
in	O
the	O
study	O
would	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
patient	O

8	O
.	O
1	O
.	O
2	O
.	O

[	O
21	O
]	O
Have	O
a	O
current	O
or	O
recent	O
(	O
<	B-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL
)	O
clinically	B-problem
serious	I-problem
viral	I-problem
,	I-problem
bacterial	I-problem
,	I-problem
fungal	I-problem
,	I-problem
or	I-problem
parasitic	I-problem
infection	I-problem
.	O

Rationale	O
for	O
Exclusion	O
of	O
Certain	O
Study	O
Candidates	O
Exclusion	O
Criteria	O

[	O
21	O
]	O
show	O
evidence	O
of	O
hepatitis	B-problem
C	I-problem
and	O
or	O
positive	B-VALUE
hepatitis	B-problem
C	I-problem
antibody	I-problem

[	O
25	O
]	O
show	O
evidence	O
of	O
hepatitis	B-problem
B	I-problem
and	O
or	O
positive	B-VALUE
hepatitis	B-test
B	I-test
surface	I-test
antigen	I-test
.	O

6	O
.	O
2	O
.	O

[	O
36	O
]	O
Have	O
clinical	B-test
laboratory	I-test
test	I-test
results	O
at	O
screening	O
that	O
are	O
outside	B-VALUE
the	I-VALUE
normal	I-VALUE
reference	I-VALUE
range	I-VALUE
for	O
the	O
population	O
and	O
are	O
considered	O
clinically	O
significant	O
,	O
and	O
or	O
have	O
any	O
of	O
the	O
following	O
specific	O
abnormalities	O
[	O
36a	O
]	O

[	O
49	O
]	O
Have	O
other	B-test
clinical	I-test
laboratory	I-test
test	I-test
results	O
at	O
screening	O
that	O
are	O
outside	B-VALUE
the	I-VALUE
normal	I-VALUE
reference	I-VALUE
range	I-VALUE
for	O
the	O
population	O
and	O
are	O
considered	O
clinically	O
significant	O
,	O
per	O
investigator	O
assessment	O
Other	O
Exclusions	O

Exclusion	O
criterion	O

LY3337641	O
I8K	O
-	O
MC	O
-	O
JPDE	O

[	O
13	O
]	O
have	O
previously	O
completed	O
or	O
withdrawn	O
from	O
this	O
study	O
or	O
any	O
other	O
study	O
investigating	O
LY3337641	O
,	O
and	O
have	O
previously	O
received	O
the	O
investigational	O
product	O

The	O
following	O
birth	B-treatment
control	I-treatment
methods	O
are	O
considered	O
highly	O
effective	O
(	O
the	O
patient	O
should	O
choose	O
2	O
to	O
be	O
used	O
with	O
their	O
male	O
partner	O
)	O
o	O
oral	B-treatment
,	I-treatment
injectable	I-treatment
,	I-treatment
or	I-treatment
implanted	I-treatment
hormonal	I-treatment
contraceptives	I-treatment
o	O
condom	B-treatment
with	I-treatment
a	I-treatment
spermicidal	I-treatment
foam	I-treatment
,	O
gel	B-treatment
,	O
film	B-treatment
,	O
cream	B-treatment
,	O
or	O
suppository	B-treatment
o	I-treatment
occlusive	I-treatment
cap	I-treatment
(	O
diaphragm	B-treatment
or	I-treatment
cervical	I-treatment
vault	I-treatment
caps	I-treatment
)	O
with	O
a	B-treatment
spermicidal	I-treatment
foam	I-treatment
,	O
gel	B-treatment
,	O
film	B-treatment
,	O
cream	B-treatment
,	O
or	O
suppository	B-treatment
o	I-treatment
intrauterine	I-treatment
device	I-treatment
o	I-treatment
intrauterine	I-treatment
system	I-treatment
(	O
for	O
example	O
,	O
progestin	B-treatment
-	I-treatment
releasing	I-treatment
coil	I-treatment
)	O
o	O
vasectomized	O
male	O
(	O
with	O
appropriate	O
post	O
-	O
vasectomy	O
documentation	O
of	O
the	O
absence	O
of	O
sperm	O
in	O
the	O
ejaculate	O
)	O

[	O
15	O
]	O
Have	O
prior	O
,	O
concurrent	O
,	O
or	O
recent	O
use	O
of	O
ixekizumab	B-treatment
or	O
any	B-treatment
other	I-treatment
biological	I-treatment
psoriasis	I-treatment
therapy	I-treatment

A	O
woman	O
aged	O
55	O
years	O
with	O
a	O
diagnosis	O
of	O
menopause	B-problem
who	O
has	O
not	O
yet	O
started	O
hormone	B-treatment
replacement	I-treatment
therapy	I-treatment
.	I-treatment

[	O
13	O
]	O
have	O
or	O
had	O
a	B-problem
herpes	I-problem
zoster	I-problem
or	O
any	B-problem
other	I-problem
clinically	I-problem
apparent	I-problem
varicella	I-problem
-	I-problem
zoster	I-problem
virus	I-problem
infection	I-problem
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL

A	O
.	O
Women	O
of	O
childbearing	O
potential	O
must	O
test	O
negative	B-VALUE
for	O
pregnancy	B-test
as	O
indicated	O
by	O
a	O
negative	B-VALUE
pregnancy	B-test
test	I-test
at	B-TEMPORAL
screening	I-TEMPORAL
followed	O
by	O
a	O
negative	B-VALUE
serum	B-test
pregnancy	I-test
test	I-test
within	B-TEMPORAL
24	I-TEMPORAL
hours	I-TEMPORAL
of	I-TEMPORAL
exposure	I-TEMPORAL
.	O

[	O
6	O
]	O
are	O
reliable	O
and	O
willing	O
to	O
make	O
themselves	O
available	O
for	O
the	O
duration	O
of	O
the	O
study	O
and	O
are	O
willing	O
to	O
follow	O
study	O
procedures	O

Note	O

The	O
choice	O
to	O
perform	O
either	O
a	B-test
TST	I-test
or	O
an	B-test
interferon	I-test
release	I-test
test	I-test
will	O
be	O
made	O
by	O
the	O
investigator	O
according	O
to	O
local	O
licensing	O
and	O
standard	O
of	O
care	O
.	O

[	O
11	O
]	O
have	O
participated	O
,	O
within	O
the	O
last	O
30	O
days	O
,	O
in	O
a	O
clinical	O
trial	O
involving	O
an	O
IP	O
.	O

b	O
.	O

At	O
screening	O
(	O
Visit	O
1	O
)	O
,	O
have	O
a	O
creatinine	O
clearance	O
(	O
80	B-VALUE
mL	I-VALUE
min	I-VALUE
,	O
using	O
Cockcroft	O
-	O
Gault	O
formula	O
)	O

If	O
the	O
previous	O
IP	O
has	O
a	O
long	O
half	O
-	O
life	O
,	O
5	B-TEMPORAL
half	I-TEMPORAL
-	I-TEMPORAL
lives	I-TEMPORAL
or	I-TEMPORAL
30	I-TEMPORAL
days	I-TEMPORAL
(	I-TEMPORAL
whichever	I-TEMPORAL
is	I-TEMPORAL
longer	I-TEMPORAL
)	I-TEMPORAL
should	O
have	O
passed	O

[	O
51	O
]	O
Are	O
investigator	O
site	O
personnel	O
directly	O
affiliated	O
with	O
this	O
study	O
and	O
or	O
their	O
immediate	O
families	O
.	O



[	O
1	O
]	O
are	O
overtly	O
healthy	O
males	O
and	O
females	O
,	O
as	O
determined	O
by	O
medical	O
history	O
and	O
physical	O
examination	O

at	O
least	O
4	O
weeks	O
prior	O
to	O
baseline	O
(	O
Week	O
0	O

Subjects	O
are	O
eligible	O
to	O
be	O
included	O
in	O
the	O
study	O
only	O
if	O
they	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
Disease	O
Characteristics	O

[	O
26	O
]	O
have	O
an	O
average	B-treatment
weekly	I-treatment
alcohol	I-treatment
intake	I-treatment
that	O
exceeds	B-VALUE
21	I-VALUE
units	I-VALUE
per	I-VALUE
week	I-VALUE
and	O
are	O
unwilling	O
to	O
follow	O
instructions	O
in	O
Section	O
6	O
.	O
3	O
.	O
2	O
(	O
1	O
unit	O
=12	O
ounces	O
or	O
360	O
mL	O
of	O
beer	O
,	O
5	O
ounces	O
or	O
150	O
mL	O
of	O
wine	O
,	O
and	O
1	O
.	O
5	O
ounces	O
or	O
45	O
mL	O
of	O
distilled	O
spirits	O
)	O

o	O
sulfasalazine	B-treatment
(	I-treatment
SSZ	I-treatment
)	I-treatment

Patients	O
who	O
have	O
documented	O
anti	B-problem
-	I-problem
HCV	I-problem
treatment	I-problem
for	O
a	O
past	O
HCV	B-problem
infection	I-problem
AND	O
are	O
HCV	B-test
RNA	I-test
-	O
negative	B-VALUE
may	O
be	O
enrolled	O
in	O
the	O
study	O
.	O

total	B-test
bilirubin	I-test
level	I-test
(	O
subjects	O
with	O
Gilberts	B-problem
syndrome	I-problem
must	O
have	O
serum	B-test
direct	I-test
bilirubin	I-test
<	B-VALUE
1	I-VALUE
.	I-VALUE
5	I-VALUE
mg	I-VALUE
dL	I-VALUE
)	O
and	O
alkaline	B-test
phosphatase	I-test
(	I-test
ALP	I-test
)	I-test
<	B-VALUE
1	I-VALUE
.	I-VALUE
5	I-VALUE
ULN	I-VALUE

[	O
4	O
]	O
Are	O
male	O
or	O
female	O
patients	O
of	O
18	O
years	O
or	O
older	O
Patient	O
Characteristics	O

[	O
18	O
]	O
Had	O
a	B-treatment
vaccination	I-treatment
with	I-treatment
Bacillus	I-treatment
Calmette	I-treatment
-	I-treatment
Gurin	I-treatment
(	I-treatment
BCG	I-treatment
)	I-treatment
within	B-TEMPORAL
12	I-TEMPORAL
months	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
,	O
or	O
intend	O
to	O
have	O
this	O
vaccination	O
with	O
BCG	O
during	B-TEMPORAL
the	I-TEMPORAL
course	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
or	O
within	B-TEMPORAL
12	I-TEMPORAL
months	I-TEMPORAL
of	I-TEMPORAL
completing	I-TEMPORAL
treatment	I-TEMPORAL
in	I-TEMPORAL
this	I-TEMPORAL
study	I-TEMPORAL
.	O

[	O
3	O
]	O
Have	O
a	B-test
body	I-test
mass	I-test
index	I-test
(	I-test
BMI	I-test
)	I-test
of	O
18	B-VALUE
.	I-VALUE
5	I-VALUE
to	I-VALUE
40	I-VALUE
.	I-VALUE
0	I-VALUE
kg	I-VALUE
m2	I-VALUE
,	I-VALUE
inclusive	I-VALUE
,	O
at	O
screening	O
.	O

Male	O
patients	O
should	O
not	O
donate	B-problem
sperm	I-problem
during	B-TEMPORAL
this	I-TEMPORAL
period	I-TEMPORAL
.	O

Visit	O
2	O
)	O
,	O
or	O
will	O
require	O
such	O
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
in	O
consultation	O
with	O
Lilly	O
or	O
its	O
designee	O
,	O
would	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
patient	O
.	O

o	O
hydroxychloroquine	B-treatment
(	I-treatment
HCQ	I-treatment
)	I-treatment
=400	B-VALUE
mg	I-VALUE
day	I-VALUE

Body	O
temperature	O
will	O
be	O
determined	O
via	O
tympanic	B-test
or	I-test
oral	I-test
methods	I-test
.	O

Type	O
of	O
Patient	O
and	O
Disease	O
Characteristics	O

Have	O
received	O
any	B-treatment
other	I-treatment
biologic	I-treatment
therapies	I-treatment
including	O
anticytokine	B-treatment
(	O
etanercept	B-treatment
,	O
infliximab	B-treatment
,	O
certolizumab	B-treatment
,	O
adalimumab	B-treatment
,	O
golimumab	B-treatment
,	O
tocilizumab	B-treatment
,	O
anakinra	B-treatment
,	O
ustekinumab	B-treatment
,	O
etc	O
.	O
)	O
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
.	O

[	O
28	O
]	O
have	O
or	O
have	O
had	O
an	O
infection	B-problem
that	O
is	O
typical	O
of	O
an	O
immunocompromised	O
host	O
and	O
or	O
that	O
occurs	O
with	O
increased	O
incidence	O
in	O
an	O
immunocompromised	B-problem
host	I-problem
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
Pneumocystis	B-problem
jirovecii	I-problem
pneumonia	I-problem
,	O
histoplasmosis	B-problem
,	O
or	O
coccidioidomycosis	B-problem
)	O
or	O
have	O
a	O
known	B-problem
immunodeficiency	I-problem
.	O

1	B-VALUE
.	I-VALUE
5x	I-VALUE
ULN	I-VALUE

[	O
32	O
]	O
have	O
significant	B-problem
allergies	I-problem
to	I-problem
humanized	I-problem
monoclonal	I-problem
antibodies	I-problem

[	O
36	O
]	O
have	O
evidence	O
of	O
or	O
test	O
positive	B-VALUE
for	O
hepatitis	B-test
C	I-test
virus	I-test
(	I-test
HCV	I-test
)	I-test
.	O

[	O
18	O
]	O
at	O
high	O
risk	O
for	O
infection	O
fever	B-problem
of	O
100	B-VALUE
.	I-VALUE
5F	I-VALUE
(	O
38C	B-VALUE
)	O
or	O
above	O
,	O
at	O
screening	B-test
or	O
baseline	O
(	O
Day	O
1	O
)	O

[	O
35	O
]	O
are	O
immunocompromised	B-problem
per	O
investigator	O
judgment	O

AND	O
OR	O
AP	B-test
2	B-TEMPORAL
at	I-TEMPORAL
baseline	I-TEMPORAL
(	O
refer	O
Section	O
9	O
.	O
1	O
.	O
2	O
for	O
details	O
)	O

[	O
12	O
]	O
Have	O
severe	B-problem
active	I-problem
lupus	I-problem
nephritis	I-problem
,	I-problem
including	O
urine	B-test
protein	I-test
creatinine	I-test
ratio	I-test
>	B-VALUE
300	I-VALUE
mg	I-VALUE
mmol	I-VALUE
(	O
as	O
an	O
estimate	O
of	O
approximate	B-problem
proteinuria	I-problem
>	B-VALUE
3	I-VALUE
g	I-VALUE
day	I-VALUE
)	O
or	O
active	B-problem
urinary	I-problem
sediment	I-problem
with	I-problem
red	I-problem
blood	I-problem
cell	I-problem
cast	I-problem
(	I-problem
s	I-problem
)	I-problem
,	O
or	O
histological	O
evidence	O
of	O
lupus	B-problem
nephritis	I-problem
(	O
Class	O
III	O
,	O
IV	O
,	O
V	O
,	O
or	O
VI	O

Immediate	O
family	O
is	O
defined	O
as	O
a	O
spouse	O
,	O
parent	O
,	O
child	O
,	O
or	O
sibling	O
,	O
whether	O
biological	O
or	O
legally	O
adopted	O
.	O

8	O
.	O
1	O
.	O
2	O
.	O

[	O
48	O
]	O
reduce	O
the	O
potential	O
bias	O
that	O
may	O
be	O
introduced	O
at	O
the	O
study	O
site	O
.	O

[	O
37f	O
]	O

If	O
the	O
previous	O
investigational	O
product	O
has	O
a	O
long	O
half	O
-	O
life	O
,	O
3	O
months	O
or	O
5	O
half	O
-	O
lives	O
(	O
whichever	O
is	O
longer	O
)	O
should	O
have	O
passed	O

Women	O
of	O
not	O
of	O
child	O
-	O
bearing	O
potential	O
are	O
defined	O
by	O
meeting	O
at	O
least	O
1	O
of	O
the	O
following	O
criteria	O

LY3074828	O

[	O
17	O
]	O
Are	O
largely	O
or	O
wholly	O
incapacitated	O
permitting	O
little	O
or	O
no	O
self	O
-	O
care	O
,	O
such	O
as	O
being	O
bedridden	B-problem
or	O
confined	O
to	O
wheelchair	O
.	O

[	O
6	O
]	O
are	O
reliable	O
and	O
willing	O
to	O
make	O
themselves	O
available	O
for	O
the	O
duration	O
of	O
the	O
study	O
,	O
and	O
are	O
willing	O
to	O
follow	O
study	O
procedures	O
.	O

[	O
12	O
]	O
Are	O
employees	O
of	O
Lilly	O
or	O
Covance	O
.	O

[	O
34	O
]	O
had	O
Clostridium	B-problem
difficile	I-problem
(	I-problem
C	I-problem
diff	I-problem
)	I-problem
infection	I-problem
within	B-TEMPORAL
60	I-TEMPORAL
days	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
or	O
test	B-test
positive	B-VALUE
at	O
screening	O
,	O
or	O
other	B-problem
intestinal	I-problem
pathogen	I-problem
with	O
30	B-TEMPORAL
days	I-TEMPORAL
before	I-TEMPORAL
screening	I-TEMPORAL
endoscopy	I-TEMPORAL
.	O

A	O
woman	O
at	O
least	O
50	O
years	O
of	O
age	O
with	O
an	O
intact	O
uterus	O
,	O
not	O
on	O
hormone	B-treatment
therapy	I-treatment
,	O
who	O
has	O
had	O
either	O
a	O
)	O
cessation	B-treatment
of	I-treatment
menses	I-treatment
for	O
at	B-TEMPORAL
least	I-TEMPORAL
1	I-TEMPORAL
year	I-TEMPORAL
or	O
b	O
)	O
at	B-TEMPORAL
least	I-TEMPORAL
6	I-TEMPORAL
months	I-TEMPORAL
of	O
spontaneous	B-problem
amenorrhea	I-problem
with	O
a	B-treatment
follicle	I-treatment
-	I-treatment
stimulating	I-treatment
hormone	I-treatment
>	B-VALUE
40	I-VALUE
mIU	I-VALUE
mL	I-VALUE
or	O
ii	O
.	O

[	O
30	O
]	O
Have	O
evidence	O
of	O
or	O
test	O
positive	B-VALUE
for	O
hepatitis	B-test
B	I-test
virus	I-test
(	I-test
HBV	I-test
)	I-test
by	O
testing	O
1	O
)	O
positive	B-VALUE
for	O
hepatitis	B-test
B	I-test
surface	I-test
antigen	I-test
(	I-test
HBsAg	I-test
+	I-test
)	I-test
,	O
OR	O
2	O
)	O
positive	B-VALUE
for	O
anti	B-test
-	I-test
hepatitis	I-test
B	I-test
core	I-test
antibody	I-test
(	I-test
HBcAb	I-test
+	I-test
)	I-test
and	O
are	O
HBV	B-test
DNA	I-test
positive	B-VALUE
.	O
(	O
Note	O
Patients	O
who	O
are	O
HBcAb	B-test
+	I-test
and	O
HBV	B-test
DNA	I-test
negative	B-VALUE
may	O
be	O
enrolled	O
in	O
the	O
study	O
.	O

Other	B-treatment
exclusionary	I-treatment
therapies	I-treatment
include	O
the	O
following	O
o	O
chronic	B-treatment
cholinergic	I-treatment
stimulant	I-treatment
agents	I-treatment
(	O
for	O
example	O
,	O
pilocarpine	B-treatment
,	O
cevimeline	B-treatment
)	O
or	O
cyclosporine	B-treatment
eye	I-treatment
drops	I-treatment
at	O
unstable	B-VALUE
dose	I-VALUE
(	O
defined	O
as	O
having	O
a	O
change	O
in	O
prescription	O
within	B-TEMPORAL
28	I-TEMPORAL
days	I-TEMPORAL
before	I-TEMPORAL
baseline	I-TEMPORAL
)	O
or	O
planned	O
to	O
be	O
started	O
or	O
increased	O
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
o	O
an	O
increase	O
in	O
dose	O
or	O
new	O
prescription	O
of	O
chronic	B-treatment
narcotic	I-treatment
drug	I-treatment
within	B-TEMPORAL
28	I-TEMPORAL
days	I-TEMPORAL
before	I-TEMPORAL
baseline	I-TEMPORAL
(	O
or	O
planned	O
increase	O
or	O
new	O
prescription	O
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
)	O

total	B-test
white	I-test
blood	I-test
cell	I-test
(	I-test
WBC	I-test
)	I-test
count	I-test
<	B-VALUE
2500	I-VALUE
cells	I-VALUE
L	I-VALUE
(	I-VALUE
<	I-VALUE
2	I-VALUE
.	I-VALUE
50x103	I-VALUE
L	I-VALUE
or	I-VALUE
<	I-VALUE
2	I-VALUE
.	I-VALUE
50	I-VALUE
GI	I-VALUE
L	I-VALUE
)	I-VALUE

[	O
20	O
]	O
have	O
current	B-problem
herpes	I-problem
zoster	I-problem
or	I-problem
simplex	I-problem
within	B-TEMPORAL
90	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
the	I-TEMPORAL
first	I-TEMPORAL
dose	I-TEMPORAL
,	O
or	O
history	O
of	O
herpes	B-problem
zoster	I-problem
,	I-problem
such	O
as	O
disseminated	B-problem
herpes	I-problem
zoster	I-problem
involving	I-problem
multiple	I-problem
dermatomes	I-problem
,	I-problem
ocular	I-problem
involvement	I-problem
,	O
including	O
herpes	B-problem
zoster	I-problem
involving	I-problem
the	I-problem
ophthalmic	I-problem
branch	I-problem
of	I-problem
the	I-problem
trigeminal	I-problem
nerve	I-problem
.	O

[	O
28	O
]	O
Have	O
received	O
systemic	B-treatment
nonbiologic	I-treatment
psoriasis	I-treatment
therapy	I-treatment
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
oral	B-treatment
psoralen	I-treatment
and	O
ultraviolet	B-treatment
A	I-treatment
[	I-treatment
PUVA	I-treatment
]	I-treatment
light	I-treatment
therapy	I-treatment
cyclosporine	B-treatment
corticosteroids	B-treatment
methotrexate	B-treatment
oral	B-treatment
retinoids	I-treatment
mycophenolate	B-treatment
mofetil	I-treatment
thioguanine	B-treatment
hydroxyurea	B-treatment
sirolimus	B-treatment
azathioprine	B-treatment
fumaric	B-treatment
acid	I-treatment
derivatives	I-treatment
or	O
1	B-VALUE
,	O
25	B-treatment
dihydroxy	I-treatment
vitamin	I-treatment
D3	I-treatment
and	O
analogues	B-treatment
)	O
,	O
or	O
phototherapy	B-treatment
(	O
including	O
either	O
oral	B-treatment
and	I-treatment
topical	I-treatment
PUVA	I-treatment
light	I-treatment
therapy	I-treatment
,	I-treatment
ultraviolet	B-treatment
B	I-treatment
,	O
or	O
self	O
-	O
treatment	O
with	O
tanning	B-treatment
beds	I-treatment
or	O
therapeutic	B-treatment
sunbathing	I-treatment
)	O
within	B-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
first	I-TEMPORAL
admission	I-TEMPORAL
to	I-TEMPORAL
the	I-TEMPORAL
CRU	I-TEMPORAL
-	O
orHad	O
topical	B-treatment
prescription	I-treatment
psoriasis	I-treatment
treatment	I-treatment
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
corticosteroids	B-treatment
,	O
anthralin	B-treatment
,	O
calcipotriene	B-treatment
,	O
topical	B-treatment
vitamin	I-treatment
D	I-treatment
derivatives	I-treatment
,	O
retinoids	B-treatment
,	O
tazarotene	B-treatment
,	O
and	O
emollients	B-treatment
)	O
within	B-TEMPORAL
the	I-TEMPORAL
previous	I-TEMPORAL
14	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
first	I-TEMPORAL
admission	I-TEMPORAL
to	I-TEMPORAL
the	I-TEMPORAL
CRU	I-TEMPORAL
.	O

absolute	B-test
PASI	I-test
score	B-VALUE
12	I-VALUE
in	O
affected	O
skin	O
at	B-TEMPORAL
screening	I-TEMPORAL
(	I-TEMPORAL
Visit	I-TEMPORAL
1	I-TEMPORAL
)	I-TEMPORAL
and	O
baseline	B-TEMPORAL
(	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL

The	O
choice	O
to	O
perform	O
either	O
a	B-test
TST	I-test
or	O
an	B-test
interferon	I-test
release	I-test
test	I-test
will	O
be	O
made	O
by	O
the	O
investigator	O
according	O
to	O
local	O
licensing	O
and	O
standard	O
of	O
care	O
.	O

b	O
)	O
Women	O
of	O
childbearing	O
potential	O
must	O
use	O
a	B-treatment
male	I-treatment
condom	I-treatment
with	I-treatment
spermicide	I-treatment
in	O
addition	O
to	O
another	O
acceptable	O
method	O
of	O
contraception	O
from	O
the	O
following	O
list	O
placement	B-treatment
of	I-treatment
intrauterine	I-treatment
device	I-treatment
established	O
use	O
of	O
oral	B-treatment
,	I-treatment
injected	I-treatment
or	I-treatment
implanted	I-treatment
hormonal	I-treatment
contraception	I-treatment
associated	O
with	O
inhibition	O
of	O
ovulation	O
partner	O
with	O
male	B-treatment
sterilization	I-treatment
,	O
with	O
verbal	O
confirmation	O
of	O
surgical	O
success	O
bilateral	B-treatment
tubal	I-treatment
ligation	I-treatment
.	O

[	O
19	O
]	O
intends	O
to	O
use	O
over	O
-	O
the	O
-	O
counter	O
or	O
prescription	B-treatment
medication	I-treatment
within	O
14	O
days	O
prior	O
to	O
dosing	O
or	O
during	O
the	O
study	O
,	O
other	O
than	O
chronic	O
,	O
stable	O
doses	O
of	O
oral	B-treatment
contraceptives	I-treatment
or	O
hormone	B-treatment
replacement	I-treatment
therapy	I-treatment
(	O
HRT	O
)	O
or	O
thyroid	B-treatment
replacement	I-treatment
therapy	O
.	O

at	O
least	O
4	O
weeks	O
prior	O
to	O
baseline	O
(	O
Week	O
0	O

d	O
received	O
phosphodiesterase	B-treatment
-	I-treatment
4	I-treatment
inhibitors	I-treatment
(	O
apremilast	B-treatment
)	O
within	B-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
planned	I-TEMPORAL
randomization	I-TEMPORAL

[	O
22	O
]	O
are	O
women	O
who	O
are	O
lactating	B-problem

Withdrawal	O
or	O
calendar	O
methods	O
are	O
not	O
acceptable	O
.	O

[	O
7	O
]	O
Have	O
failed	B-problem
to	I-problem
respond	I-problem
to	I-problem
,	I-problem
or	I-problem
are	I-problem
intolerant	I-problem
of	I-problem
,	I-problem
at	I-problem
least	I-problem
1	I-problem
topical	I-problem
therapy	I-problem
(	I-problem
corticosteroids	I-problem
,	I-problem
calcineurin	I-problem
inhibitors	I-problem
and	I-problem
or	I-problem
vitamin	I-problem
D	I-problem
analogs	I-problem
)	I-problem
used	O
for	O
treatment	O
of	O
psoriasis	O
affecting	O
the	O
genital	O
area	O
Patient	O
Characteristics	O

re	O
women	O
40	O
and	O
<	O
60	O
years	O
of	O
age	O
who	O
have	O
had	O
a	O
cessation	B-problem
of	I-problem
menses	I-problem
for	O
at	B-TEMPORAL
least	I-TEMPORAL
1	I-TEMPORAL
year	I-TEMPORAL
,	O
have	O
a	B-test
follicle	I-test
-	I-test
stimulating	I-test
hormone	I-test
(	I-test
FSH	I-test
)	I-test
value	I-test
<	B-VALUE
40	I-VALUE
mIU	I-VALUE
mL	I-VALUE
,	O
and	O
do	O
not	O
agree	O
to	O
use	O
2	B-VALUE
forms	I-VALUE
of	O
highly	O
effective	O
methods	O
of	O
birth	B-treatment
control	I-treatment
when	O
engaging	O
in	O
sexual	O
intercourse	O
with	O
a	O
male	O
partner	O
while	O
enrolled	O
in	O
the	O
study	O
and	O
for	O
at	B-TEMPORAL
least	I-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
following	I-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
dose	I-TEMPORAL
of	I-TEMPORAL
investigational	I-TEMPORAL
product	I-TEMPORAL
,	O
unless	O
they	O
are	O
congenitally	B-treatment
or	I-treatment
surgically	I-treatment
sterile	I-treatment
(	O
that	O
is	O
,	O
have	O
had	O
a	B-treatment
hysterectomy	I-treatment
,	O
bilateral	B-treatment
oophorectomy	I-treatment
,	O
or	O
tubal	B-treatment
ligation	I-treatment
)	O
.	O

[	O
15	O
]	O
have	O
an	O
abnormal	B-VALUE
blood	B-test
pressure	I-test
or	O
pulse	B-test
rate	I-test
(	I-test
supine	I-test
)	I-test
as	O
determined	O
by	O
the	O
investigator	O

The	O
choice	O
to	O
perform	O
a	O
PPD	O
,	O
QuantiFERON	O
-	O
TB	O
Gold	O
test	O
,	O
or	O
T	O
-	O
SPOT	O
will	O
be	O
made	O
by	O
the	O
investigator	O
according	O
to	O
local	O
licensing	O
and	O
standard	O
of	O
care	O
.	O

LY3337641	O

Note	O

[	O
8	O
]	O
are	O
reliable	O
and	O
willing	O
to	O
make	O
themselves	O
available	O
for	O
the	O
duration	O
of	O
the	O
study	O
,	O
and	O
are	O
able	O
and	O
willing	O
to	O
follow	O
study	O
procedures	O

Hemoglobin	B-test
<	B-VALUE
8	I-VALUE
.	I-VALUE
5	I-VALUE
g	I-VALUE
dL	I-VALUE
(	I-VALUE
85	I-VALUE
.	I-VALUE
0	I-VALUE
g	I-VALUE
L	I-VALUE
)	I-VALUE
for	I-VALUE
male	I-VALUE
patients	I-VALUE
and	O
<	B-VALUE
8	I-VALUE
.	I-VALUE
0	I-VALUE
g	I-VALUE
dL	I-VALUE
(	I-VALUE
80	I-VALUE
g	I-VALUE
L	I-VALUE
)	I-VALUE
for	I-VALUE
female	I-VALUE
patients	I-VALUE

[	O
26	O
]	O
have	O
had	O
any	B-treatment
major	I-treatment
surgery	I-treatment
within	B-TEMPORAL
8	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL
or	O
will	O
require	O
major	B-treatment
surgery	I-treatment
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
in	O
consultation	O
with	O
Lilly	O
or	O
its	O
designee	O
,	O
would	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
patient	O

Type	O
of	O
Patient	O
and	O
Disease	O
Characteristics	O

LY2439821	O

Patients	O
are	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
only	O
if	O
they	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
at	O
screening	O
and	O
or	O
enrollment	O

[	O
22	O
]	O
are	O
women	O
who	O
are	O
pregnant	B-problem
or	O
lactating	B-problem

6	O
.	O
1	O
.	O

[	O
35	O
]	O
have	O
evidence	O
of	O
active	B-problem
hepatitis	I-problem
B	I-problem
virus	I-problem
(	O
positive	B-VALUE
for	O
hepatitis	B-test
B	I-test
surface	I-test
antigen	I-test
)	I-test
OR	O
are	O
positive	B-VALUE
for	O
hepatitis	B-test
B	I-test
core	I-test
antibody	I-test
and	O
negative	B-VALUE
for	O
hepatitis	B-test
B	I-test
surface	I-test
antibody	I-test
.	I-test

[	O
4	O
]	O
Are	O
a	O
candidate	O
for	O
phototherapy	B-treatment
and	O
or	O
systemic	B-treatment
therapy	I-treatment
.	I-treatment

[	O
45	O
]	O
Have	O
previously	O
been	O
randomized	O
in	O
this	O
study	O
or	O
any	O
other	O
study	O
investigating	O
baricitinib	O
.	O

Note	O
Patients	O
with	O
history	O
of	O
malignancy	B-problem
with	O
no	O
evidence	O
of	O
recurrence	B-problem
or	I-problem
active	I-problem
disease	I-problem
within	B-TEMPORAL
5	I-TEMPORAL
years	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
may	O
participate	O
in	O
the	O
study	O
.	O

Exception	O
Patients	O
with	O
a	O
history	O
of	O
latent	B-problem
TB	I-problem
who	O
have	O
documented	O
evidence	O
of	O
appropriate	B-treatment
treatment	I-treatment
,	O
have	O
no	O
history	O
of	O
re	B-treatment
-	I-treatment
exposure	I-treatment
since	B-TEMPORAL
their	I-TEMPORAL
treatment	I-TEMPORAL
was	I-TEMPORAL
completed	I-TEMPORAL
,	O
and	O
have	O
a	O
screening	O
chest	B-test
x	I-test
-	I-test
ray	I-test
with	O
no	O
evidence	O
of	O
active	B-problem
TB	I-problem
may	O
be	O
enrolled	O
if	O
other	O
entry	O
criteria	O
met	O
.	O

I1F	O
-	O
MC	O
-	O
RHBU	O
Clinical	O
Pharmacology	O
Protocol	O

Gold	O
test	O
or	O
T	O
-	O
SPOT	O

Exclusion	O
Criteria	O

platelet	B-test
count	I-test
<	B-VALUE
100	I-VALUE
,	I-VALUE
000	I-VALUE
cells	I-VALUE
L	I-VALUE

Subjects	O
are	O
eligible	O
to	O
be	O
included	O
in	O
the	O
study	O
only	O
if	O
they	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
at	O
screening	O
Type	O
of	O
Subject	O
and	O
Disease	O
Characteristics	O

[	O
1	O
]	O
Present	O
with	O
moderate	B-problem
-	I-problem
to	I-problem
-	I-problem
severe	I-problem
chronic	I-problem
plaque	I-problem
psoriasis	I-problem
based	O
on	O
a	O
diagnosis	O
of	O
chronic	B-problem
psoriasis	I-problem
for	O
at	B-TEMPORAL
least	I-TEMPORAL
6	I-TEMPORAL
months	I-TEMPORAL
before	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
,	O
as	O
determined	O
by	O
the	O
investigator	O

[	O
7	O
]	O
have	O
venous	B-test
access	I-test
sufficient	I-test
to	O
allow	O
for	O
blood	O
sampling	O
and	O
administration	O
of	O
IP	O
as	O
per	O
the	O
protocol	O

LY3090106	O
I6M	O
-	O
JE	O
-	O
SSAA	O

Lymphocyte	B-test
count	I-test
<	B-VALUE
500	I-VALUE
cells	I-VALUE
L	I-VALUE
.	O
[	O
51c	O
]	O

[	O
11	O
]	O
have	O
an	O
adequate	O
organ	O
function	O
,	O
including	O

[	O
44	O
]	O
At	O
screening	O
,	O
have	O
a	B-test
lymphocyte	I-test
count	I-test
<	B-VALUE
800	I-VALUE
cells	I-VALUE
L	I-VALUE
(	I-VALUE
<	I-VALUE
0	I-VALUE
.	I-VALUE
80x103	I-VALUE
L	I-VALUE
or	I-VALUE
<	I-VALUE
0	I-VALUE
.	I-VALUE
80	I-VALUE
GI	I-VALUE
L	I-VALUE
)	I-VALUE

The	B-test
AST	I-test
and	O
ALT	B-test
may	O
be	O
repeated	O
once	B-TEMPORAL
within	I-TEMPORAL
a	I-TEMPORAL
week	I-TEMPORAL
if	O
the	O
initial	O
response	O
exceeds	O
this	O
limit	O
,	O
and	O
the	O
repeat	O
value	O
may	O
be	O
accepted	O
if	O
it	O
is	O
less	O
than	O
the	O
criterion	O
limits	O
.	O

[	O
26	O
]	O
have	O
a	O
history	O
of	O
clinically	B-problem
significant	I-problem
multiple	I-problem
or	I-problem
severe	I-problem
drug	I-problem
allergies	I-problem
or	O
a	O
history	O
of	O
severe	B-problem
posttreatment	I-problem
hypersensitivity	I-problem
reactions	I-problem
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
erythema	B-problem
multiforme	I-problem
major	I-problem
,	O
linear	B-problem
IgA	I-problem
dermatosis	I-problem
,	O
toxic	B-problem
epidermal	I-problem
necrolysis	I-problem
,	O
or	O
exfoliative	B-problem
dermatitis	I-problem
)	I-problem

Such	O
patients	O
would	O
not	O
be	O
required	O
to	O
undergo	O
the	B-test
protocol	I-test
-	I-test
specific	I-test
TB	I-test
testing	I-test
for	O
PPD	O
,	O
QuantiFERON	O
-	O
TB	O

[	O
26	O
]	O
regularly	O
consume	O
an	B-problem
excessive	I-problem
amount	I-problem
of	I-problem
caffeine	I-problem
,	I-problem
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
or	O
are	O
unwilling	O
to	O
abide	O
by	O
restrictions	O
as	O
specified	O
in	O
Section	O
6	O
.	O
3	O
.	O
2	O

Class	B-treatment
6	I-treatment
(	O
mild	O
,	O
such	O
as	O
desonide	B-treatment
)	O
or	O
Class	B-treatment
7	I-treatment
(	O
least	O
potent	O
,	O
such	O
as	O
hydrocortisone	B-treatment
)	O
topical	O
steroids	O
will	O
be	O
permitted	O
for	O
use	O
limited	O
to	O
the	O
face	O
,	O
axilla	O
,	O
and	O
or	O
genitalia	O
.	O

Patients	O
will	O
be	O
excluded	O
from	O
study	O
enrollment	O
if	O
they	O
meet	O
any	O
of	O
the	O
following	O
criteria	O
at	O
screening	O
(	O
Visit	O
1	O
)	O

The	O
following	O
therapies	O
are	O
permitted	O
during	O
the	O
study	O
,	O
at	O
stable	O
doses	O
parenteral	B-treatment
MTX	I-treatment
up	B-VALUE
to	I-VALUE
20	I-VALUE
mg	I-VALUE
week	I-VALUE

If	O
the	B-test
QuantiFERON	I-test
-	I-test
TB	I-test
Gold	I-test
is	O
indeterminate	B-VALUE
or	O
the	O
T	O
-	O
Spot	O
.	O

[	O
29	O
]	O
have	O
previously	O
completed	O
or	O
withdrawn	O
from	O
this	O
study	O
or	O
any	O
other	O
study	O
investigating	O
LY3074828	O
.	O

Investigators	O
should	O
review	O
the	O
vaccination	O
status	O
of	O
their	O
patients	O
and	O
follow	O
the	O
local	O
guidelines	O
for	O
adult	O
vaccination	O
with	O
nonlive	O
vaccines	O
intended	O
to	O
prevent	O
infectious	O
disease	O
prior	O
to	O
therapy	O
.	O
(	O
Note	O
Killed	O
inactive	O
or	O
subunit	O
vaccines	O
are	O
expected	O
to	O
be	O
safe	O
)	O

[	O
31	O
]	O
show	O
evidence	O
of	O
active	B-problem
or	I-problem
latent	I-problem
tuberculosis	I-problem
(	I-problem
TB	I-problem
)	I-problem
,	O
as	O
documented	O
by	O
medical	O
history	O
and	O
examination	O
,	O
chest	O
x	O
-	O
rays	O
(	O
posterior	O
anterior	O
and	O
lateral	O
)	O
,	O
and	O
TB	O
testing	O
to	O
qualify	O
for	O
the	O
study	O
,	O
subject	O
must	O
have	O
either	O
a	O
negative	B-VALUE
tuberculin	B-test
skin	I-test
test	I-test
(	I-test
TST	I-test
defined	O
as	O
a	B-test
skin	I-test
induration	I-test
<	B-VALUE
5	I-VALUE
mm	I-VALUE
at	I-VALUE
48	I-VALUE
hours	I-VALUE
to	I-VALUE
72	I-VALUE
hours	I-VALUE
,	O
regardless	O
of	O
BCG	B-test
[	I-test
Bacillus	I-test
Calmette	I-test
-	I-test
Guerin	I-test
]	I-test
or	O
other	B-treatment
vaccination	I-treatment
history	O
)	O
,	O
or	O
a	O
negative	B-VALUE
(	I-VALUE
not	I-VALUE
indeterminate	I-VALUE
)	I-VALUE
QuantiFERON	B-test
-	I-test
TB	I-test
Gold	I-test
test	I-test
.	O

[	O
20	O
]	O
Have	O
active	B-problem
Crohns	I-problem
disease	I-problem
(	I-problem
CD	I-problem
)	I-problem
or	O
active	B-problem
ulcerative	I-problem
colitis	I-problem
(	I-problem
UC	I-problem
)	I-problem
.	O

[	O
12	O
]	O
have	O
a	O
history	O
of	O
adverse	B-problem
drug	I-problem
reactions	I-problem
or	O
drug	B-problem
allergy	I-problem
to	O
more	B-VALUE
than	I-VALUE
3	I-VALUE
types	I-VALUE
of	O
systemically	O
administered	O
medications	O
(	O
all	B-treatment
penicillins	I-treatment
and	I-treatment
cephalosporins	I-treatment
may	O
be	O
considered	O
1	B-VALUE
type	I-VALUE
of	O
medication	O
for	O
this	O
purpose	O
)	O
.	O

[	O
36f	O
]	O

[	O
50	O
]	O
Have	O
severe	B-problem
active	I-problem
lupus	I-problem
nephritis	I-problem
,	O
including	O
urine	B-test
protein	I-test
creatinine	I-test
ratio	I-test
>	B-VALUE
300	I-VALUE
mg	I-VALUE
mmol	I-VALUE
(	O
as	O
an	O
estimate	O
of	O
approximate	B-problem
proteinuria	I-problem
>	B-VALUE
3g	I-VALUE
day	I-VALUE
)	O
or	O
active	B-problem
urinary	I-problem
sediment	I-problem
with	I-problem
red	I-problem
blood	I-problem
cell	I-problem
cast	I-problem
(	I-problem
s	I-problem
)	I-problem
,	O
or	O
histological	O
evidence	O
(	O
if	O
available	O
)	O
of	O
diffuse	B-problem
proliferative	I-problem
glomerulonephritis	I-problem
within	B-TEMPORAL
the	I-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL
.	O

[	O
21	O
]	O
show	O
evidence	O
of	O
hepatitis	B-problem
B	I-problem
,	I-problem
and	O
or	O
positive	B-VALUE
hepatitis	B-test
B	I-test
surface	I-test
antigen	I-test
,	I-test
and	O
or	O
hepatitis	B-test
B	I-test
core	I-test
antibody	I-test

[	O
24	O
]	O
have	O
had	O
lymphoma	B-problem
,	O
leukemia	B-problem
,	O
or	O
any	B-problem
malignancy	I-problem
within	B-TEMPORAL
the	I-TEMPORAL
past	I-TEMPORAL
5	I-TEMPORAL
years	I-TEMPORAL
,	I-TEMPORAL
except	O
for	O
basal	B-problem
cell	I-problem
or	O
squamous	B-problem
epithelial	I-problem
carcinomas	I-problem
of	I-problem
the	I-problem
skin	I-problem
that	O
have	O
been	O
resected	O
with	O
no	O
evidence	O
of	O
metastatic	B-problem
disease	I-problem
for	O
3	B-TEMPORAL
years	I-TEMPORAL
and	O
cervical	B-problem
carcinoma	I-problem
in	I-problem
situ	I-problem
,	O
with	O
no	O
e	B-problem
vidence	I-problem
of	I-problem
recurrence	I-problem
within	B-TEMPORAL
the	I-TEMPORAL
5	I-TEMPORAL
years	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL

[	O
40	O
]	O
Are	O
currently	O
enrolled	O
in	O
any	O
other	O
clinical	O
trial	O
involving	O
an	O
investigational	O
product	O
or	O
any	O
other	O
type	O
of	O
medical	O
research	O
judged	O
not	O
to	O
be	O
scientifically	O
or	O
medically	O
compatible	O
with	O
this	O
study	O

[	O
31	O
]	O
have	O
donated	O
more	B-problem
than	I-problem
a	I-problem
single	I-problem
unit	I-problem
of	I-problem
blood	I-problem
within	B-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL
or	O
intend	O
to	O
donate	B-problem
blood	I-problem
during	B-TEMPORAL
the	I-TEMPORAL
course	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
Other	O
Exclusions	O

total	B-test
white	I-test
blood	I-test
cell	I-test
count	I-test
<	B-VALUE
2500	I-VALUE
cells	I-VALUE
L	I-VALUE
(	I-VALUE
<	I-VALUE
2	I-VALUE
.	I-VALUE
50	I-VALUE
103	I-VALUE
L	I-VALUE
or	I-VALUE
<	I-VALUE
2	I-VALUE
.	I-VALUE
50	I-VALUE
GI	I-VALUE
L	I-VALUE
)	I-VALUE

For	O
non	O
-	O
childbearing	O
potential	O
female	O
patients	O
,	O
patients	O
must	O
be	O
women	O
who	O
have	O
had	O
surgical	B-treatment
sterilization	I-treatment
(	O
hysterectomy	B-treatment
,	O
bilateral	B-treatment
oophorectomy	I-treatment
,	I-treatment
or	O
tubal	B-treatment
ligation	I-treatment
)	I-treatment
,	I-treatment
-	O
orwomen	O
who	O
are	O
60	O
years	O
of	O
age	O
,	O
-	O
or	O
-	O
(	O
FSH	O
)	O
test	O
confirming	O
nonchildbearing	O
potential	O
(	O
40	O
mIU	O
mL	O
)	O

Two	B-VALUE
effective	O
methods	O
of	O
contraception	B-treatment
will	O
be	O
used	O
.	O

Otherwise	O
,	O
women	O
of	O
childbearing	O
potential	O
must	O
agree	O
to	O
use	O
1	B-VALUE
highly	B-treatment
effective	I-treatment
(	I-treatment
<	I-treatment
1%	I-treatment
failure	I-treatment
rate	I-treatment
)	I-treatment
method	I-treatment
of	I-treatment
contraception	I-treatment
or	O
use	O
a	O
combination	O
of	O
2	B-VALUE
effective	B-treatment
methods	I-treatment
of	I-treatment
contraception	I-treatment
during	B-TEMPORAL
treatment	I-TEMPORAL
and	O
for	B-TEMPORAL
28	I-TEMPORAL
days	I-TEMPORAL
after	I-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
dose	I-TEMPORAL
of	O
LY3337641	O
.	O

[	O
24	O
]	O
show	O
evidence	O
of	O
hepatitis	B-problem
B	I-problem
and	O
or	O
positive	B-VALUE
hepatitis	B-test
B	I-test
surface	I-test
antigen	I-test
or	O
positive	B-VALUE
hepatitis	B-test
B	I-test
core	I-test
antibody	I-test
(	I-test
HBcAb	I-test
+	I-test
)	I-test
at	O
screening	O

x	O
ULN	O
(	O
if	O
available	O
)	O
.	O

[	O
19	O
]	O
show	O
evidence	O
of	O
human	B-problem
immunodeficiency	I-problem
virus	I-problem
(	I-problem
HIV	I-problem
)	I-problem
infection	I-problem
and	O
or	O
positive	B-VALUE
human	B-test
HIV	I-test
antibodies	I-test

6	O
.	O
2	O
.	O

[	O
24	O
]	O
Have	O
electrocardiogram	B-problem
(	I-problem
ECG	I-problem
)	I-problem
abnormalities	I-problem
that	O
are	O
considered	O
clinically	O
significant	O
and	O
would	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
patient	O
if	O
participating	O
in	O
the	O
study	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
.	O

I1F	O
-	O
MC	O
-	O
RHBU	O
Clinical	O
Pharmacology	O
Protocol	O
(	O
Note	O
Patients	O
with	O
successfully	O
treated	O
basal	B-problem
-	I-problem
cell	I-problem
carcinoma	I-problem
[	O
no	B-VALUE
more	I-VALUE
than	I-VALUE
3	I-VALUE
]	O
,	O
squamous	B-problem
-	I-problem
cell	I-problem
carcinoma	I-problem
of	I-problem
the	I-problem
skin	I-problem
,	O
or	O
cervical	B-problem
carcinoma	I-problem
in	I-problem
situ	I-problem
,	O
with	O
no	O
evidence	O
of	O
recurrence	O
within	B-TEMPORAL
the	I-TEMPORAL
5	I-TEMPORAL
years	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
first	I-TEMPORAL
admission	I-TEMPORAL
to	I-TEMPORAL
the	I-TEMPORAL
CRU	I-TEMPORAL
may	O
participate	O
in	O
the	O
study	O
.	O
)	O

[	O
34	O
]	O
Are	O
women	O
who	O
are	O
planning	O
to	O
become	O
pregnant	O
,	O
who	O
are	O
pregnant	B-problem
,	O
or	O
who	O
are	O
breast	B-problem
-	I-problem
feeding	I-problem
Infections	O

[	O
30	O
]	O
Have	O
received	O
oral	O
or	O
parenteral	O
[	O
intravenous	O
(	O
IV	O
)	O
or	O
intramuscular	O
(	O
IM	O
)	O
]	O

[	O
42	O
]	O
Are	O
investigator	O
site	O
personnel	O
directly	O
affiliated	O
with	O
this	O
study	O
and	O
or	O
their	O
immediate	O
families	O
.	O

[	O
33	O
]	O
have	O
significant	B-problem
allergies	I-problem
to	I-problem
humanized	I-problem
monoclonal	I-problem
antibodies	I-problem

[	O
30	O
]	O
Have	O
concurrent	O
use	O
or	O
have	O
received	O
any	O
of	O
the	O
following	O
biologic	O
agents	O
within	B-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
year	I-TEMPORAL
human	B-treatment
growth	I-treatment
hormone	I-treatment
(	I-treatment
hGH	I-treatment
)	I-treatment
,	O
interferons	B-treatment
,	O
rituximab	B-treatment
,	O
efalizumab	B-treatment
,	O
tocilizumab	B-treatment
or	O
other	B-treatment
agents	I-treatment
that	I-treatment
target	I-treatment
interleukin	I-treatment
-	I-treatment
6	I-treatment
,	I-treatment
interferons	I-treatment
,	I-treatment
basiliximab	I-treatment
or	O
other	B-treatment
agents	I-treatment
that	I-treatment
target	I-treatment
IL	I-treatment
-	I-treatment
2	I-treatment
,	O
muromonab	B-treatment
or	O
other	B-treatment
agents	I-treatment
that	I-treatment
target	I-treatment
CD3	I-treatment
,	O
canakinumab	B-treatment
or	O
other	B-treatment
agents	I-treatment
that	I-treatment
target	I-treatment
IL	I-treatment
-	I-treatment
1	I-treatment
,	O
or	O
Cimzia	B-treatment
(	I-treatment
certolizumab	I-treatment
pegol	I-treatment
)	I-treatment
or	O
have	O
concurrent	O
use	O
or	O
have	O
received	O
any	O
of	O
the	O
following	O
biologic	O
agents	O
with	O
the	O
following	O
washout	O
periods	O
alefacept	B-treatment
,	O
or	O
any	B-treatment
agents	I-treatment
that	I-treatment
target	I-treatment
Tumor	I-treatment
Necrosis	I-treatment
Factor	I-treatment
(	O
such	O
as	O
Remicade	B-treatment
[	I-treatment
infliximab	I-treatment
]	I-treatment
,	O
Humira	B-treatment
[	I-treatment
adalimumab	I-treatment
]	I-treatment
,	I-treatment
or	O
Enbrel	B-treatment
[	I-treatment
etanercept	I-treatment
]	I-treatment
)	I-treatment
,	I-treatment
(	O
<	B-VALUE
60	I-VALUE
days	I-VALUE
)	O
,	O
ustekinumab	B-treatment
or	O
other	B-treatment
agents	I-treatment
that	I-treatment
target	I-treatment
IL	I-treatment
-	I-treatment
12	I-treatment
or	I-treatment
IL	I-treatment
-	I-treatment
23	I-treatment
,	O
(	O
<	B-VALUE
8	I-VALUE
months	I-VALUE
)	O
,	O
Simponi	B-treatment
(	I-treatment
golimumab	I-treatment
)	I-treatment
(	O
<	B-VALUE
90	I-VALUE
days	I-VALUE
)	O
or	O
any	B-treatment
other	I-treatment
biologic	I-treatment
agent	I-treatment
<	B-TEMPORAL
5	I-TEMPORAL
half	I-TEMPORAL
-	I-TEMPORAL
lives	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
first	I-TEMPORAL
admission	I-TEMPORAL
to	I-TEMPORAL
the	I-TEMPORAL
CRU	I-TEMPORAL
.	O

[	O
15	O
]	O
have	O
sepsis	B-problem
or	O
risk	B-problem
of	I-problem
sepsis	I-problem

LY3074828	O
I6T	O
-	O
MC	O
-	O
AMAG	O
(	O
b	O
)	O

[	O
13	O
]	O
Have	O
received	O
natalizumab	B-treatment
or	O
other	B-treatment
agents	I-treatment
targeting	I-treatment
4	I-treatment
integrin	O

Other	O
Exclusions	O

a	O
)	O

[	O
26	O
]	O
Have	O
active	B-problem
tuberculosis	I-problem
(	I-problem
TB	I-problem
)	I-problem
determined	O
on	O
the	O
basis	O
of	O
a	O
positive	B-VALUE
medical	B-test
history	I-test
,	O
physical	B-test
examination	I-test
,	O
or	O
chest	B-test
radiography	I-test
(	O
per	O
local	O
standard	O
of	O
care	O
)	O
or	O
have	O
exclusionary	B-test
TB	I-test
test	I-test
results	O
,	O
which	O
include	O
either	O
of	O
the	O
following	O
a	O
positive	B-VALUE
tuberculin	B-test
skin	I-test
test	I-test
(	I-test
TST	I-test
)	I-test
result	O
(	O
defined	O
as	O
a	B-test
skin	I-test
induration	I-test
>	B-VALUE
5	I-VALUE
mm	I-VALUE
at	O
48	B-TEMPORAL
to	I-TEMPORAL
72	I-TEMPORAL
hours	I-TEMPORAL
after	I-TEMPORAL
the	I-TEMPORAL
test	I-TEMPORAL
date	I-TEMPORAL
,	O
regardless	O
of	O
Bacillus	O
Calmette	O
-	O
Gurin	O
vaccination	O
history	O
)	O
or	O
a	O
positive	B-VALUE
(	O
or	O
persistently	B-VALUE
indeterminate	I-VALUE
invalid	I-VALUE
borderline	I-VALUE
)	O
interferon	B-test
-	I-test
release	I-test
test	I-test
(	O
for	O
example	O
,	O
QuantiFERON	O
-	O
TB	O

[	O
29	O
]	O
have	O
had	O
symptomatic	B-problem
herpes	I-problem
zoster	I-problem
within	B-TEMPORAL
3	I-TEMPORAL
months	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
,	O
as	O
determined	O
by	O
clinical	O
history	O

Subjects	O
whose	O
results	O
are	O
anti	B-test
-	I-test
HCVAb	I-test
positive	B-VALUE
and	O
HCV	B-test
RNA	I-test
negative	B-VALUE
can	O
be	O
enrolled	O
in	O
the	O
study	O
,	O
according	O
to	O
investigator	O
judgment	O
.	O

[	O
24	O
]	O
have	O
the	O
presence	O
of	O
significant	B-problem
uncontrolled	I-problem
cerebrocardiovascular	I-problem
disorder	I-problem
(	O
for	O
example	O
,	O
MI	B-problem
,	O
unstable	B-problem
angina	I-problem
,	O
unstable	B-problem
arterial	I-problem
hypertension	I-problem
,	O
moderate	B-problem
to	I-problem
severe	I-problem
[	I-problem
New	I-problem
York	I-problem
Heart	I-problem
Association	I-problem
class	I-problem
III	I-problem
IV	I-problem
]	I-problem
heart	I-problem
failure	I-problem
,	O
or	O
cerebrovascular	B-problem
accident	I-problem
)	O
respiratory	B-problem
,	I-problem
hepatic	I-problem
,	I-problem
renal	I-problem
,	I-problem
gastrointestinal	I-problem
,	I-problem
endocrine	I-problem
,	I-problem
hematologic	I-problem
,	I-problem
neurologic	I-problem
,	I-problem
or	I-problem
neuropsychiatric	I-problem
disorder	I-problem
or	O
abnormal	B-VALUE
laboratory	B-test
values	I-test
at	O
screening	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
patient	O
if	O
participating	O
in	O
the	O
study	O
or	O
risk	O
of	O
interfering	O
with	O
the	O
interpretation	O
of	O
data	O
.	O

[	O
20	O
]	O
Have	O
a	O
history	O
of	O
lymphoproliferative	B-problem
disease	I-problem
or	O
have	O
signs	O
or	O
symptoms	O
suggestive	O
of	O
possible	O
lymphoproliferative	B-problem
disease	I-problem
,	O
including	O
lymphadenopathy	B-problem
or	O
splenomegaly	B-problem
(	O
other	O
than	O
primarily	O
due	O
to	O
SLE	O
)	O
or	O
have	O
active	B-problem
primary	I-problem
or	I-problem
recurrent	I-problem
malignant	I-problem
disease	I-problem
or	O
have	O
been	O
in	O
remission	O
from	O
clinically	B-problem
significant	I-problem
malignancy	I-problem
for	O
<	B-TEMPORAL
5	I-TEMPORAL
years	I-TEMPORAL
.	O

[	O
3	O
]	O
are	O
candidates	O
for	O
phototherapy	B-treatment
or	O
systemic	B-treatment
treatment	I-treatment
or	O
considered	O
by	O
the	O
investigator	O
as	O
not	O
adequately	O
controlled	O
by	O
topical	B-treatment
therapies	I-treatment
Subject	O
Characteristics	O

[	O
38	O
]	O
have	O
participated	O
,	O
within	O
the	O
last	O
30	O
days	O
,	O
in	O
a	O
clinical	O
study	O
involving	O
an	O
investigational	O
product	O
.	O

A	O
woman	O
aged	O
55	O
years	O
or	O
older	O
who	O
is	O
not	O
on	O
hormone	B-treatment
therapy	I-treatment
and	O
has	O
had	O
at	B-TEMPORAL
least	I-TEMPORAL
6	I-TEMPORAL
months	I-TEMPORAL
of	O
spontaneous	B-problem
amenorrhea	I-problem
or	O
iii	O
.	O

Aspartate	B-test
aminotransferase	I-test
(	I-test
AST	I-test
)	I-test
or	O
alanine	B-test
aminotransferase	I-test
(	I-test
ALT	I-test
)	I-test
>	B-VALUE
2	I-VALUE
.	I-VALUE
5	I-VALUE
times	I-VALUE
the	I-VALUE
upper	I-VALUE
limit	I-VALUE
of	I-VALUE
normal	I-VALUE
(	I-VALUE
ULN	I-VALUE
)	I-VALUE
.	O

[	O
41	O
]	O
At	B-TEMPORAL
screening	I-TEMPORAL
,	O
have	O
a	O
total	B-test
white	I-test
blood	I-test
cell	I-test
(	I-test
WBC	I-test
)	I-test
count	I-test
<	B-VALUE
3000	I-VALUE
cells	I-VALUE
L	I-VALUE
(	I-VALUE
<	I-VALUE
3	I-VALUE
.	I-VALUE
00x103	I-VALUE
L	I-VALUE
or	I-VALUE
<	I-VALUE
3	I-VALUE
.	I-VALUE
00	I-VALUE
GI	I-VALUE
L	I-VALUE
)	I-VALUE
.	O

[	O
4	O
]	O
Have	O
sPGA	B-test
of	I-test
Genitalia	I-test
3	B-VALUE
at	O
screening	O
(	O
Visit	O
1	O
)	O
and	O
at	B-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
,	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL

Inclusion	O
Criteria	O

Other	O

[	O
36	O
]	O
Have	O
or	O
had	O
an	B-problem
infection	I-problem
typical	O
of	O
an	O
immunocompromised	O
host	O
and	O
or	O
that	O
occurs	O
with	O
increased	O
incidence	O
in	O
an	B-problem
immunocompromised	I-problem
host	O
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
Pneumocystis	B-problem
jirovecii	I-problem
pneumonia	I-problem
,	O
histoplasmosis	B-problem
,	O
or	O
coccidioidomycosis	B-problem
)	I-problem
or	O
have	O
a	B-problem
known	I-problem
immunodeficiency	I-problem

[	O
4	O
]	O
male	O
and	O
female	O
subjects	O
from	O
6	O
to	O
<	O
18	O
years	O
of	O
age	O
at	O
time	O
of	O
randomization	O

f	O
neutropenia	B-problem
(	O
absolute	B-test
neutrophil	I-test
count	I-test
[	I-test
ANC	I-test
]	I-test
<	O
1200	O
cells	O
L	O
)	O
(	B-VALUE
<	I-VALUE
1	I-VALUE
.	I-VALUE
20	I-VALUE
x	I-VALUE
103	I-VALUE
L	I-VALUE
or	I-VALUE
<	I-VALUE
1	I-VALUE
.	I-VALUE
20	I-VALUE
GI	I-VALUE
L	I-VALUE
)	I-VALUE

[	O
31a	O
]	O

LY2439821	B-test
(	I-test
FSH	I-test
)	I-test
test	I-test
confirming	O
non	O
-	O
childbearing	O
potential	O
(	O
40	B-VALUE
mIU	I-VALUE
mL	I-VALUE
)	O
.	O

If	O
the	O
previous	O
investigational	O
product	O
has	O
a	O
long	O
half	O
-	O
life	O
,	O
3	O
months	O
or	O
5	O
half	O
-	O
lives	O
(	O
whichever	O
is	O
longer	O
)	O
should	O
have	O
passed	O

[	O
30	O
]	O
Have	O
evidence	O
of	O
or	O
test	O
positive	B-VALUE
for	O
hepatitis	B-test
C	I-test
virus	I-test
(	I-test
HCV	I-test
)	I-test
.	O

[	O
24	O
]	O
have	O
donated	B-problem
blood	I-problem
of	O
more	B-VALUE
than	I-VALUE
450	I-VALUE
mL	I-VALUE
within	B-TEMPORAL
3	I-TEMPORAL
months	I-TEMPORAL
of	I-TEMPORAL
study	I-TEMPORAL
enrollment	I-TEMPORAL

[	O
16	O
]	O
exclude	O
patients	O
who	O
are	O
taking	O
concomitant	O
medications	O
or	O
receiving	O
treatment	O
or	O
phototherapy	O
that	O
could	O
have	O
a	O
negative	O
safety	O
impact	O
on	O
the	O
patients	O
enrolled	O
or	O
confound	O
the	O
results	O
of	O
the	O
study	O
.	O

[	O
4	O
]	O
Have	O
both	O
an	B-test
sPGA	I-test
score	B-VALUE
of	I-VALUE
3	I-VALUE
and	O
PASI	B-test
score	B-VALUE
12	I-VALUE
at	O
screening	O
(	O
Visit	O
1	O
)	O
and	O
baseline	O
(	O
Week	O
0	O

[	O
52	O
]	O
Have	O
any	O
other	O
condition	O
that	O
precludes	O
the	O
patient	O
from	O
following	O
and	O
completing	O
the	O
protocol	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O

[	O
46	O
]	O
Show	O
evidence	O
of	O
active	B-problem
or	I-problem
latent	I-problem
tuberculosis	I-problem
(	I-problem
TB	I-problem
)	I-problem
,	O
as	O
documented	O
by	O
medical	O
history	O
and	O
physical	O
examination	O
,	O
chest	O
x	O
-	O
rays	O
(	O
posterior	O
anterior	O
and	O
lateral	O
)	O
,	O
and	O
TB	O
testing	O
lack	O
of	O
TB	O
will	O
be	O
demonstrated	O
by	O
either	O
a	O
negative	B-VALUE
purified	B-test
protein	I-test
derivative	I-test
(	I-test
PPD	I-test
)	I-test
test	I-test
(	O
defined	O
as	O
a	B-test
skin	I-test
induration	I-test
<	B-VALUE
5	I-VALUE
mm	I-VALUE
at	O
48	B-TEMPORAL
to	I-TEMPORAL
72	I-TEMPORAL
hours	I-TEMPORAL
,	O
regardless	O
of	O
BCG	O
or	O
other	O
vaccination	O
history	O
)	O
or	O
a	O
negative	B-VALUE
(	I-VALUE
not	I-VALUE
indeterminate	I-VALUE
)	I-VALUE
QuantiFERON	B-test
-	I-test
TB	I-test
Gold	I-test
test	I-test
or	O
T	B-test
-	I-test
SPOT	I-test
.	O

If	O
a	O
male	O
patient	O
,	O
agree	O
to	O
use	O
a	O
reliable	O
method	O
of	O
birth	B-treatment
control	I-treatment
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
and	O
for	O
at	B-TEMPORAL
least	I-TEMPORAL
6	I-TEMPORAL
month	I-TEMPORAL
following	I-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
dose	I-TEMPORAL
of	I-TEMPORAL
investigational	I-TEMPORAL
product	I-TEMPORAL
.	O

[	O
18	O
]	O
Have	O
ever	O
received	O
treatment	B-treatment
with	I-treatment
IL	I-treatment
-	I-treatment
17	I-treatment
antagonists	I-treatment
such	O
as	O
ixekizumab	B-treatment
,	I-treatment
secukinumab	B-treatment
,	O
or	O
brodalumab	B-treatment
Vaccinations	O

[	O
19	O
]	O
Are	O
unwilling	O
to	O
comply	O
with	O
the	B-treatment
dietary	I-treatment
requirements	I-treatment
restrictions	I-treatment
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
(	O
i	O
)	O
consume	O
only	O
the	O
meals	B-treatment
provided	I-treatment
during	B-TEMPORAL
the	I-TEMPORAL
inpatient	I-TEMPORAL
visits	I-TEMPORAL
,	O
and	O
(	O
ii	O
)	O
refrain	O
from	O
consuming	B-problem
grapefruit	I-problem
,	I-problem
Seville	I-problem
oranges	I-problem
,	I-problem
star	I-problem
fruit	I-problem
,	I-problem
pomelos	I-problem
,	I-problem
or	I-problem
products	I-problem
containing	I-problem
these	I-problem
fruits	I-problem
,	O
for	O
at	B-TEMPORAL
least	I-TEMPORAL
14	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
the	I-TEMPORAL
first	I-TEMPORAL
administration	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
drug	I-TEMPORAL
cocktail	I-TEMPORAL
through	I-TEMPORAL
the	I-TEMPORAL
end	I-TEMPORAL
of	I-TEMPORAL
Week	I-TEMPORAL
12	I-TEMPORAL
assessments	I-TEMPORAL
.	O

total	B-test
white	I-test
blood	I-test
cell	I-test
(	I-test
WBC	I-test
)	I-test
count	I-test
<	B-VALUE
3000	I-VALUE
cells	I-VALUE
L	I-VALUE

c	O
.	O
hemoglobin	B-test
<	B-VALUE
8	I-VALUE
.	I-VALUE
5	I-VALUE
g	I-VALUE
dL	I-VALUE
(	I-VALUE
<	I-VALUE
85	I-VALUE
.	I-VALUE
0	I-VALUE
g	I-VALUE
L	I-VALUE
)	I-VALUE

[	O
6	O
]	O
are	O
reliable	O
and	O
willing	O
to	O
make	O
themselves	O
available	O
for	O
the	O
duration	O
of	O
the	O
study	O
and	O
are	O
willing	O
to	O
follow	O
study	O
procedures	O

while	O
engaging	O
in	O
sexual	O
intercourse	O
with	O
female	O
partners	O
of	O
childbearing	O
potential	O
while	B-TEMPORAL
enrolled	I-TEMPORAL
in	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
and	O
for	O
at	B-TEMPORAL
least	I-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
following	I-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
dose	I-TEMPORAL
of	I-TEMPORAL
investigational	I-TEMPORAL
product	I-TEMPORAL
b	O
Female	O
patients	O
of	O
childbearing	O
potential	O
must	O
agree	O
to	O
use	O
2	B-VALUE
forms	I-VALUE
of	O
birth	B-treatment
control	I-treatment
,	I-treatment
when	O
engaging	O
in	O
sexual	O
intercourse	O
with	O
a	O
male	O
partner	O
while	B-TEMPORAL
enrolled	I-TEMPORAL
in	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
and	O
for	O
at	B-TEMPORAL
least	I-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
following	I-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
dose	I-TEMPORAL
of	I-TEMPORAL
investigational	I-TEMPORAL
product	I-TEMPORAL

[	O
12	O
]	O
have	O
participated	O
,	O
within	B-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
30	I-TEMPORAL
days	I-TEMPORAL
,	O
in	O
a	B-test
clinical	I-test
study	I-test
involving	I-test
an	I-test
IP	I-test
.	O

prescription	O
for	O
oral	B-treatment
prednisone	I-treatment
(	I-treatment
or	I-treatment
equivalent	I-treatment
)	I-treatment
>	B-VALUE
10	I-VALUE
mg	I-VALUE
day	I-VALUE
or	O
UNSTABLE	O
PRESCRIBED	O
DOSE	O
within	B-TEMPORAL
28	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
a	B-treatment
chronic	I-treatment
narcotic	I-treatment
drug	I-treatment
at	O
an	O
UNSTABLE	O
PRESCRIBED	O
DOSE	O
within	B-TEMPORAL
28	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
or	O
planned	O
increase	B-treatment
new	I-treatment
prescription	I-treatment
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
gemfibrozil	B-treatment
(	O
a	O
strong	O
cytochrome	O
P450	O
2C8	O
inhibitor	O
)	O
or	O
alfentanil	B-treatment
,	I-treatment
dihydroergotamine	B-treatment
,	O
dofetilide	B-treatment
,	O
ergotamine	B-treatment
,	O
fentanyl	B-treatment
,	O
pimozide	B-treatment
,	O
or	O
quinidine	B-treatment
(	O
sensitive	O
narrow	O
therapeutic	O
index	O
cytochrome	O
P450	O
3A	O
substrates	O
)	O
within	B-TEMPORAL
28	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
or	O
planned	O
treatment	O
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL

If	O
the	B-test
test	I-test
results	O
are	O
not	O
negative	B-VALUE
,	O
the	O
patient	O
will	O
be	O
considered	O
to	O
have	O
latent	B-problem
TB	I-problem
(	O
for	O
purposes	O
of	O
this	O
study	O
)	O
and	O
will	O
be	O
excluded	O
.	O

[	O
1	O
]	O
are	O
overtly	O
healthy	O
males	O
or	O
females	O
,	O
as	O
determined	O
by	O
medical	O
history	O
and	O
physical	O
examination	O

[	O
6	O
]	O
are	O
reliable	O
and	O
willing	O
to	O
make	O
themselves	O
available	O
for	O
the	O
duration	O
of	O
the	O
study	O
and	O
are	O
willing	O
to	O
follow	O
study	O
procedures	O

[	O
19	O
]	O
Had	O
a	B-treatment
live	I-treatment
vaccination	I-treatment
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
,	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
,	O
intend	O
to	O
have	O
a	B-treatment
live	I-treatment
vaccination	I-treatment
during	B-TEMPORAL
the	I-TEMPORAL
course	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
or	O
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
completing	I-TEMPORAL
treatment	I-TEMPORAL
in	I-TEMPORAL
this	I-TEMPORAL
study	I-TEMPORAL
,	O
or	O
have	O
participated	O
in	O
a	B-test
vaccine	I-test
clinical	I-test
study	I-test
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
.	O

Subjects	O
will	O
be	O
excluded	O
if	O
they	O
were	O
exposed	O
to	O
herpes	B-treatment
zoster	I-treatment
vaccination	I-treatment
within	B-TEMPORAL
6	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
randomization	I-TEMPORAL
.	O

If	O
the	O
QuantiFERON	B-test
-	I-test
TB	I-test
Gold	I-test
test	I-test
is	O
indeterminate	B-VALUE
,	O
a	O
retest	O
using	O
the	O
same	O
type	O
of	O
test	O
(	O
that	O
is	O
,	O
QuantiFERON	B-test
test	I-test
instead	O
of	O
PPD	B-test
test	I-test
)	I-test
is	O
allowed	O
.	O

[	O
5	O
]	O
have	O
a	B-test
body	I-test
weight	I-test
of	O
40	B-VALUE
.	I-VALUE
0	I-VALUE
kg	I-VALUE
or	I-VALUE
higher	I-VALUE
for	I-VALUE
Cohorts	I-VALUE
1	I-VALUE
to	I-VALUE
4	I-VALUE
and	O
48	B-VALUE
.	I-VALUE
0	I-VALUE
kg	I-VALUE
or	I-VALUE
higher	I-VALUE
for	I-VALUE
Cohort	I-VALUE
5	I-VALUE

[	O
6	O
]	O
Have	O
confirmation	O
of	O
plaque	B-problem
psoriasis	I-problem
in	I-problem
a	I-problem
nongenital	I-problem
area	I-problem
at	O
at	O
screening	O
(	O
Visit1	O
)	O
and	O
baseline	B-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
,	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL

[	O
9	O
]	O
are	O
Lilly	O
employees	O
.	O

Patients	O
who	O
are	O
HBcAb	B-test
+	I-test
and	O
HBV	B-test
DNA	I-test
negative	B-VALUE
may	O
be	O
enrolled	O
in	O
the	O
study	O
.	O

Prior	O
Concurrent	O
Clinical	O
Trial	O
Experience	O

[	O
23	O
]	O
have	O
a	B-problem
concomitant	I-problem
autoimmune	I-problem
or	I-problem
connective	I-problem
tissue	I-problem
disease	I-problem
at	O
screening	O
that	O
is	O
deemed	O
active	O
enough	O
to	O
interfere	O
with	O
the	O
subjects	O
safety	O
or	O
with	O
evaluation	O
of	O
RA	O
disease	O
activity	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O

Enrollment	O
Criteria	O

ii	O
postmenopausal	O
as	O
evidenced	O
by	O
spontaneous	B-problem
amenorrhea	I-problem
for	O
at	B-TEMPORAL
least	I-TEMPORAL
12	I-TEMPORAL
months	I-TEMPORAL

[	O
22	O
]	O
are	O
women	O
who	O
are	O
lactating	B-problem

[	O
28	O
]	O
have	O
an	B-test
ANC	I-test
<	B-VALUE
2000	I-VALUE
cells	I-VALUE
L	I-VALUE
(	I-VALUE
2	I-VALUE
109	I-VALUE
L	I-VALUE
)	I-VALUE
at	O
screening	O
.	O

[	O
28	O
]	O
Have	O
any	B-problem
other	I-problem
active	I-problem
or	I-problem
recent	I-problem
infection	I-problem
within	B-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
patient	O
if	O
participating	O
in	O
the	O
study	O
these	O
patients	O
may	O
be	O
rescreened	O
(	O
1	O
time	O
)	O
4	O
or	O
more	O
weeks	O
after	O
documented	O
resolution	O
of	O
symptoms	O
.	O

LY3337641	O
I8K	O
-	O
MC	O
-	O
JPDE	O

If	O
the	O
test	O
is	O
not	O
negative	O
,	O
the	O
test	O
may	O
be	O
repeated	O
once	O
within	O
approximately	O
2	O
weeks	O
of	O
the	O
initial	O
value	O
.	O

TB	B-test
is	O
invalid	B-VALUE
or	O
borderline	B-VALUE
,	O
one	B-VALUE
retest	B-test
is	O
allowed	O
according	O
to	O
investigator	O
judgment	O
.	O

[	O
17	O
]	O
Have	O
had	O
any	B-treatment
major	I-treatment
surgery	I-treatment
within	B-TEMPORAL
8	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
or	O
will	O
require	O
major	B-treatment
surgery	I-treatment
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
in	O
consultation	O
with	O
Lilly	O
or	O
its	O
designee	O
,	O
would	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
subject	O
.	O

ultraviolet	B-treatment
-	I-treatment
A	I-treatment
therapy	I-treatment
,	O
ultraviolet	B-treatment
-	I-treatment
B	I-treatment
therapy	I-treatment
,	O
and	O
topical	B-treatment
treatments	I-treatment
(	O
except	O
on	O
face	O
,	O
scalp	O
,	O
and	O
genital	O
area	O
during	O
screening	O
)	O
in	B-TEMPORAL
the	I-TEMPORAL
previous	I-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL

re	O
Lilly	O
employees	O
or	O
are	O
employees	O
of	O
third	O
-	O
party	O
organizations	O
involved	O
in	O
the	O
study	O

The	B-test
repeat	I-test
laboratory	I-test
test	I-test
does	O
not	O
require	O
a	O
reconsent	O
because	O
the	O
result	O
does	O
not	O
constitute	O
a	O
screening	O
failure	O
until	O
the	O
clinically	O
significant	O
out	O
-	O
of	O
-	O
range	O
value	O
is	O
confirmed	O
.	O

o	O

[	O
32	O
]	O
have	O
had	O
serious	B-problem
,	I-problem
opportunistic	I-problem
,	I-problem
or	I-problem
chronic	I-problem
recurring	I-problem
infection	I-problem
within	B-TEMPORAL
6	I-TEMPORAL
months	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL
.	O

Clinical	O
Protocol	O

[	O
1a	O
]	O

[	O
12	O
]	O
Have	O
concurrent	O
or	O
recent	O
use	O
of	O
any	B-treatment
biologic	I-treatment
agent	I-treatment
within	B-TEMPORAL
the	I-TEMPORAL
following	I-TEMPORAL
washout	I-TEMPORAL
periods	I-TEMPORAL
etanercept	B-treatment
<	B-TEMPORAL
28	I-TEMPORAL
days	I-TEMPORAL
infliximab	B-treatment
,	O
adalimumab	B-treatment
,	O
or	O
alefacept	B-treatment
<	B-TEMPORAL
60	I-TEMPORAL
days	I-TEMPORAL
golimumab	B-treatment
<	B-TEMPORAL
90	I-TEMPORAL
days	I-TEMPORAL
ustekinumab	B-treatment
<	B-TEMPORAL
8	I-TEMPORAL
months	I-TEMPORAL
rituximab	B-treatment
or	O
efalizumab	B-treatment
<	B-TEMPORAL
12	I-TEMPORAL
months	I-TEMPORAL
or	O
any	B-treatment
other	I-treatment
biologic	I-treatment
agent	I-treatment
<	B-TEMPORAL
5	I-TEMPORAL
half	I-TEMPORAL
-	I-TEMPORAL
lives	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL

[	O
15	O
]	O
Have	O
previously	O
failed	O
to	O
respond	O
to	O
an	B-treatment
IL	I-treatment
-	I-treatment
17	I-treatment
antagonist	I-treatment
,	I-treatment
per	O
investigator	O
assessment	O
.	O

[	O
40	O
]	O
have	O
screening	O
laboratory	O
test	O
values	O
,	O
including	O
thyroid	B-treatment
-	I-treatment
stimulating	I-treatment
hormone	I-treatment
(	I-treatment
TSH	I-treatment
)	I-treatment
outside	B-TEMPORAL
the	I-TEMPORAL
reference	I-TEMPORAL
range	I-TEMPORAL
for	O
the	O
population	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
pose	O
an	O
unacceptable	O
risk	O
for	O
the	O
patients	O
participation	O
in	O
the	O
study	O
Patients	O
who	O
are	O
receiving	O
thyroxine	B-treatment
as	I-treatment
replacement	I-treatment
therapy	I-treatment
may	O
participate	O
in	O
the	O
study	O
provided	O
that	O
stable	O
therapy	O
has	O
been	O
administered	O
for	O
12	B-TEMPORAL
weeks	I-TEMPORAL
and	O
TSH	B-test
is	O
within	B-VALUE
the	I-VALUE
laboratorys	I-VALUE
reference	I-VALUE
range	I-VALUE
.	O

[	O
29	O
]	O
are	O
immunocompromised	B-problem

Vaccinations	O

[	O
18	O
]	O
Had	O
a	B-treatment
vaccination	I-treatment
with	I-treatment
Bacillus	I-treatment
Calmette	I-treatment
-	I-treatment
Gurin	I-treatment
(	I-treatment
BCG	I-treatment
)	I-treatment
within	B-TEMPORAL
12	I-TEMPORAL
months	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
,	O
or	O
intend	O
to	O
have	O
this	B-treatment
vaccination	I-treatment
with	I-treatment
BCG	I-treatment
during	B-TEMPORAL
the	I-TEMPORAL
course	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
,	O
or	O
within	B-TEMPORAL
12	I-TEMPORAL
months	I-TEMPORAL
of	I-TEMPORAL
completing	I-TEMPORAL
treatment	I-TEMPORAL
in	O
this	O
study	O
.	O

Additionally	O
a	O
)	O
women	O
of	O
childbearing	O
potential	O
must	O
test	O
negative	B-VALUE
for	O
pregnancy	B-test
prior	B-TEMPORAL
to	I-TEMPORAL
initiation	I-TEMPORAL
of	I-TEMPORAL
treatment	I-TEMPORAL
based	O
on	O
a	B-test
serum	I-test
pregnancy	I-test
test	I-test
at	B-TEMPORAL
the	I-TEMPORAL
screening	I-TEMPORAL
visit	I-TEMPORAL
and	O
on	O
Day	O

[	O
17	O
]	O
have	O
received	O
any	O
of	O
the	O
following	O
for	O
treatment	O
of	O
Crohns	O
disease	O

[	O
21	O
]	O
presence	O
of	O
significant	B-problem
uncontrolled	I-problem
cerebrocardiovascular	I-problem
disorder	I-problem
(	O
eg	O
,	O
unstable	B-problem
arterial	I-problem
hypertension	I-problem
,	O
moderate	O
-	O
to	O
-	O
severe	O

If	O
the	B-test
repeat	I-test
test	I-test
is	O
also	O
indeterminate	B-VALUE
,	O
the	O
subject	O
will	O
be	O
excluded	O
.	O

e	O
total	B-test
white	I-test
blood	I-test
cell	I-test
(	I-test
WBC	I-test
)	I-test
count	I-test
<	B-VALUE
2500	I-VALUE
cells	I-VALUE
L	I-VALUE
(	I-VALUE
<	I-VALUE
2	I-VALUE
.	I-VALUE
50	I-VALUE
x	I-VALUE
103	I-VALUE
L	I-VALUE
or	I-VALUE
<	I-VALUE
2	I-VALUE
.	I-VALUE
50	I-VALUE
GI	I-VALUE
L	I-VALUE
)	I-VALUE

e	O
.	O

Gold	O
(	O
QTF	O
)	O
or	O
T	O
-	O
SPOT	O
.	O
TB	O
(	O
T	O
-	O
SPOT	O
)	O
test	O
.	O

[	O
4	O
]	O
have	O
a	B-test
body	I-test
mass	I-test
index	I-test
of	O
19	B-VALUE
.	I-VALUE
0	I-VALUE
to	I-VALUE
24	I-VALUE
.	I-VALUE
0	I-VALUE
kg	I-VALUE
m2	I-VALUE
,	I-VALUE
inclusive	I-VALUE
,	O
at	O
screening	O
.	O

Immediate	O
family	O
is	O
defined	O
as	O
a	O
spouse	O
,	O
parent	O
,	O
child	O
,	O
or	O
sibling	O
,	O
whether	O
biological	O
or	O
legally	O
adopted	O
.	O

[	O
18	O
]	O
current	O
or	O
recent	O
history	O
(	O
<	B-TEMPORAL
30	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL
of	O
a	O
clinically	O
significant	O
bacterial	O
,	O
fungal	O
,	O
parasitic	O
,	O
viral	O
(	O
not	O
including	O
rhinopharyngitis	B-problem
)	O
,	O
or	O
mycobacterial	O
infection	O
.	O

[	O
1	O
]	O
are	O
overtly	O
healthy	O
males	O
or	O
female	O
subjects	O
,	O
as	O
determined	O
by	O
medical	O
history	O
and	O
physical	O
examination	O
.	O

Subjects	O
whose	O
results	O
are	O
HBcAb	B-test
positive	B-VALUE
and	O
HBV	B-test
DNA	I-test
negative	B-VALUE
at	O
screening	O
will	O
be	O
identified	O
by	O
the	O
central	O
laboratory	O
and	O
monitored	O
for	O
HBV	B-problem
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
as	O
detailed	O
in	O
Section	O
8	O
.	O
4	O
.	O
7	O
.	O
1	O
and	O
in	O
the	O
Schedule	O
of	O
Activities	O
(	O
Appendix	O
2	O
)	O
.	O

Male	O
patients	O
agree	O
to	O
use	O
a	O
reliable	O
method	O
of	O
contraception	B-treatment
and	O
not	O
donate	B-problem
sperm	I-problem
for	O
the	O
duration	B-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL

Male	O
patients	O
must	O
agree	O
to	O
use	O
2	B-VALUE
forms	I-VALUE
of	O
birth	B-treatment
control	I-treatment
(	O
one	B-VALUE
must	O
be	O
highly	B-treatment
effective	I-treatment
,	O
see	O
below	O
)	O

[	O
1b	O
]	O
female	O
subjects	O
women	O
of	O
childbearing	O
potential	O
may	O
participate	O
and	O
include	O
those	O
who	O
test	O
negative	B-VALUE
for	O
pregnancy	B-test
prior	B-TEMPORAL
to	I-TEMPORAL
initiation	I-TEMPORAL
of	I-TEMPORAL
treatment	I-TEMPORAL
(	O
as	O
indicated	O
by	O
a	O
negative	B-VALUE
serum	B-test
pregnancy	I-test
test	I-test
at	O
the	O
screening	O
visit	O
followed	O
by	O
a	O
negative	B-VALUE
urine	B-test
pregnancy	I-test
test	I-test
within	B-TEMPORAL
24	I-TEMPORAL
hours	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
exposure	I-TEMPORAL
)	O
and	O
agree	O
to	O
remain	O
abstinent	B-treatment
or	O
use	O
either	O
1	B-VALUE
highly	B-treatment
effective	I-treatment
method	I-treatment
of	I-treatment
contraception	I-treatment
(	O
such	O
as	O
combination	O
oral	B-treatment
contraceptive	I-treatment
,	O
implanted	B-treatment
contraceptive	I-treatment
,	O
or	O
intrauterine	B-treatment
device	I-treatment
)	I-treatment
or	O
a	O
combination	O
of	O
2	B-VALUE
effective	B-treatment
methods	I-treatment
of	I-treatment
contraception	I-treatment
(	O
such	O
as	O
male	B-treatment
or	I-treatment
female	I-treatment
condom	I-treatment
with	I-treatment
spermicide	I-treatment
,	O
diaphragm	B-treatment
with	I-treatment
spermicide	I-treatment
,	O
or	O
cervical	B-treatment
sponge	I-treatment
)	O
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
and	O
for	O
4	B-TEMPORAL
weeks	I-TEMPORAL
following	I-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
dose	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
IP	I-TEMPORAL
women	O
not	O
of	O
childbearing	O
potential	O
may	O
participate	O
and	O
include	O
those	O
who	O
are	O
A	O
.	O
infertile	O
due	O
to	O
surgical	B-treatment
sterilization	I-treatment
(	O
hysterectomy	B-treatment
,	O
bilateral	B-treatment
oophorectomy	I-treatment
,	I-treatment
or	O
tubal	B-treatment
ligation	I-treatment
)	I-treatment
performed	B-TEMPORAL
at	I-TEMPORAL
least	I-TEMPORAL
6	I-TEMPORAL
months	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
dosing	I-TEMPORAL
or	O
congenital	B-problem
anomaly	I-problem
such	O
as	O
mllerian	B-problem
agenesis	I-problem
or	O
LY3337641	O
I8K	O
-	O
JE	O
-	O
JPDB	O
Clinical	O
Pharmacology	O
Protocol	O

[	O
30	O
]	O
are	O
immunocompromised	B-problem

[	O
6	O
]	O
patients	O
must	O
be	O
categorized	O
into	O
1	O
of	O
the	O
following	O
2	O
strata	O
a	O
bDMARD	O
-	O
nave	O
patients	O
who	O
have	O
active	B-problem
PsA	I-problem
despite	O
current	O
or	O
prior	O
NSAIDs	B-treatment
or	O
cDMARDs	B-treatment
and	O
have	O
never	O
received	O
bDMARD	B-treatment
treatment	I-treatment
,	I-treatment
or	O
b	O
TNF	O
-	O
IR	O
have	O
been	O
treated	O
at	O
approved	O
doses	O
with	O
at	B-VALUE
least	I-VALUE
1	I-VALUE
TNFi	B-treatment
(	O
for	O
example	O
,	O
adalimumab	B-treatment
,	O
certolizumab	B-treatment
,	O
golimumab	B-treatment
,	O
etanercept	B-treatment
,	O
infliximab	B-treatment
)	O
for	O
at	B-TEMPORAL
least	I-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
and	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
either	O
o	O
experienced	O
insufficient	B-problem
efficacy	I-problem
or	O
loss	B-problem
of	I-problem
efficacy	I-problem
at	O
a	O
dose	O
that	O
,	O
in	O
accordance	O
with	O
local	O
clinical	O
practice	O
,	O
is	O
considered	O
acceptable	O
to	O
adequately	O
assess	O
clinical	O
response	O
or	O
o	O
experienced	O
intolerance	B-problem
of	I-problem
such	I-problem
treatment	I-problem
(	O
the	O
12	O
weeks	O
treatment	O
period	O
with	O
TNFi	O
is	O
not	O
required	O
in	O
case	O
of	O
intolerance	O
)	O
Patient	O
Characteristics	O

[	O
39	O
]	O
have	O
had	O
lymphoma	B-problem
,	O
leukemia	B-problem
,	O
or	O
any	B-problem
malignancy	I-problem
within	B-TEMPORAL
the	I-TEMPORAL
past	I-TEMPORAL
5	I-TEMPORAL
years	I-TEMPORAL
except	O
for	O
basal	B-problem
cell	I-problem
or	O
squamous	B-problem
epithelial	I-problem
carcinomas	I-problem
of	I-problem
the	I-problem
skin	I-problem
that	O
have	O
been	O
resected	O
with	O
no	O
evidence	O
of	O
metastatic	B-problem
disease	I-problem
for	O
3	B-TEMPORAL
years	I-TEMPORAL

Exception	O
Patients	O
who	O
have	O
evidence	O
of	O
latent	B-problem
TB	I-problem
may	O
be	O
enrolled	O
if	O
he	O
she	O
completes	O
at	O
least	O
4	O
weeks	O
of	O
appropriate	B-treatment
treatment	I-treatment
prior	O
to	O
randomization	O
and	O
agrees	O
to	O
complete	O
the	O
remainder	O
of	O
treatment	O
while	O
in	O
the	O
trial	O
.	O

Subjects	O
will	O
be	O
excluded	O
from	O
study	O
enrollment	O
if	O
they	O
meet	O
any	O
of	O
the	O
following	O
criteria	O
at	O
screening	O
and	O
or	O
enrollment	O

[	O
42	O
]	O
Have	O
or	O
had	O
an	B-problem
infection	I-problem
typical	I-problem
of	I-problem
an	I-problem
immunocompromised	I-problem
host	I-problem
,	O
and	O
or	O
that	O
occurs	O
with	O
increased	O
incidence	O
in	O
an	O
immunocompromised	O
host	O
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
Pneumocystis	B-problem
jirovecii	I-problem
pneumonia	I-problem
,	O
histoplasmosis	B-problem
,	O
or	O
coccidioidomycosis	B-problem
)	O
or	O
have	O
a	B-problem
known	I-problem
immunodeficiency	I-problem
.	O

[	O
5	O
]	O
both	O
the	O
child	O
or	O
adolescent	O
and	O
a	O
parent	O
or	O
legal	O
guardian	O
are	O
able	O
to	O
understand	O
and	O
fully	O
participate	O
in	O
the	O
activities	O
of	O
the	O
clinical	O
study	O
and	O
sign	O
their	O
assent	O
and	O
consent	O
,	O
respectively	O

at	B-TEMPORAL
least	I-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
,	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
and	O
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
,	O
per	O
investigator	O
assessment	O

Subjects	O
with	O
known	O
latent	B-problem
TB	I-problem
should	O
not	O
undergo	O
a	B-test
TST	I-test
or	O
interferon	B-test
release	I-test
test	I-test
and	O
must	O
have	O
documentation	O
of	O
receiving	O
at	O
least	O
4	O
weeks	O
of	O
appropriate	O
,	O
ongoing	B-treatment
latent	I-treatment
TB	I-treatment
therapy	I-treatment
,	O
according	O
to	O
local	O
standard	O
of	O
care	O
,	O
prior	O
to	O
screening	O
.	O

55	O
years	O
of	O
age	O
not	O
on	O
hormone	B-treatment
therapy	I-treatment
,	O
who	O
has	O
had	O
at	B-TEMPORAL
least	I-TEMPORAL
6	I-TEMPORAL
months	I-TEMPORAL
of	O
spontaneous	B-problem
amenorrhea	I-problem
or	O
o	O
a	O
woman	O
at	O
least	O
55	O
years	O
of	O
age	O
with	O
a	O
diagnosis	O
of	O
menopause	B-problem
prior	B-TEMPORAL
to	I-TEMPORAL
starting	I-TEMPORAL
hormone	I-TEMPORAL
replacement	I-TEMPORAL
therapy	I-TEMPORAL
.	O

[	O
22	O
]	O
Presence	O
of	O
significant	B-problem
uncontrolled	I-problem
cerebro	I-problem
-	I-problem
cardiovascular	I-problem
condition	I-problem
(	O
for	O
example	O
,	O
myocardial	B-problem
infarction	I-problem
[	I-problem
MI	I-problem
]	I-problem
,	O
unstable	B-problem
angina	I-problem
,	O
unstable	B-problem
arterial	I-problem
hypertension	I-problem
,	O
moderate	O
-	O
to	O
-	O
severe	O

If	O
the	B-test
repeat	I-test
value	I-test
is	O
less	O
than	O
the	O
criterion	O
limits	O
,	O
the	O
second	O
value	O
may	O
be	O
accepted	O
.	O
)	O

[	O
2	O
]	O
are	O
aged	O
18	O
to	O
65	O
years	O
,	O
inclusive	O
at	O
screening	O

but	O
must	O
have	O
a	O
chest	O
x	O
-	O
ray	O
at	O
screening	O
.	O

QuantiFERON	B-treatment
-	I-treatment
TB	I-treatment
Gold	I-treatment
Plus	I-treatment
test	I-treatment
(	I-treatment
QFT	I-treatment
-	I-treatment
Plus	I-treatment
or	I-treatment
equivalent	I-treatment
)	I-treatment
will	O
be	O
used	O
for	O
TB	O
testing	O
,	O
and	O
subjects	O
must	O
test	O
negative	B-VALUE
to	O
participate	O
.	O

iii	B-problem
female	I-problem
infertility	I-problem
due	O
to	O
other	O
causes	O
that	O
have	O
been	O
discussed	O
with	O
,	O
and	O
accepted	O
in	O
writing	O
,	O
by	O
the	O
sponsor	O

.	O
TB	O
test	O
(	O
as	O
available	O
and	O
if	O
compliant	O
with	O
local	O
TB	O
guidelines	O
)	O
.	O

A	O
positive	B-VALUE
test	O
for	O
HCV	B-test
is	O
defined	O
as	O
(	O
1	O
)	O
positive	B-VALUE
for	O
hepatitis	B-test
C	I-test
antibody	I-test
and	O
(	O
2	O
)	O
positive	B-VALUE
via	O
a	O
confirmatory	O
test	O
for	O
HCV	B-test
(	O
for	O
example	O
,	O
HCV	B-test
polymerase	I-test
chain	I-test
reaction	I-test
)	O
.	O

[	O
20	O
]	O
Are	O
largely	O
or	O
wholly	O
incapacitated	O
permitting	O
little	O
or	O
no	O
self	O
-	O
care	O
,	O
such	O
as	O
being	O
bedridden	B-problem
or	O
confined	O
to	O
wheelchair	O
.	O

If	O
the	O
QuantiFERON	O
-	O
TB	O

Exclusion	O
criteria	O

[	O
28	O
]	O
are	O
subjects	O
who	O
have	O
an	B-problem
average	I-problem
weekly	I-problem
alcohol	I-problem
intake	I-problem
that	O
exceeds	B-VALUE
21	I-VALUE
units	I-VALUE
per	I-VALUE
week	I-VALUE
for	I-VALUE
males	I-VALUE
and	O
14	B-VALUE
units	I-VALUE
per	I-VALUE
week	I-VALUE
for	I-VALUE
females	I-VALUE
or	O
who	O
are	O
unwilling	O
to	O
abide	O
by	O
the	O
alcohol	O
restrictions	O
described	O
in	O
Section	O
9	O
.	O
5	O

Clinical	O
Protocol	O
>	B-VALUE
40	I-VALUE
mIU	I-VALUE
mL	I-VALUE
or	O
o	O
a	O
woman	O

[	O
22	O
]	O
are	O
women	O
who	O
intend	O
to	O
become	O
pregnant	B-problem
or	O
who	O
are	O
lactating	B-problem

Methods	O
of	O
contraception	O
considered	O
acceptable	O
include	O
oral	B-treatment
contraceptives	I-treatment
,	O
contraceptive	B-treatment
patch	I-treatment
,	O
intrauterine	B-treatment
device	I-treatment
,	O
vaginal	B-treatment
ring	I-treatment
,	O
diaphragm	B-treatment
with	I-treatment
contraceptive	I-treatment
gel	O
,	O
or	O
condom	B-treatment
with	I-treatment
contraceptive	I-treatment
gel	I-treatment

[	O
19	O
]	O
show	O
evidence	O
of	O
HIV	B-problem
infection	I-problem
and	O
or	O
positive	B-VALUE
human	B-test
HIV	I-test
antibodies	I-test

[	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
class	O
III	O
IV	O
]	O
heart	O
failure	O
,	O
or	O
cerebrovascular	B-problem
accident	I-problem
[	I-problem
CVA	I-problem
]	I-problem
)	O
,	O
respiratory	O
,	O
hepatic	O
,	O
renal	O
,	O
gastrointestinal	O
,	O
endocrine	O
,	O
hematologic	O
,	O
neurologic	O
or	O
neuropsychiatric	O
disorders	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
patient	O
if	O
participating	O
in	O
the	O
study	O
or	O
of	O
interfering	O
with	O
the	O
interpretation	O
of	O
data	O
.	O

LY3074828	O
I6T	O
-	O
MC	O
-	O
AMAL	O

[	O
11	O
]	O
Have	O
experienced	O
a	B-problem
clinically	I-problem
significant	I-problem
thrombotic	I-problem
event	I-problem
within	B-TEMPORAL
24	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
or	O
are	O
on	O
anticoagulants	B-treatment
and	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
are	O
not	O
well	O
controlled	O
.	O

TB	O
is	O
invalid	B-VALUE
or	O
borderline	B-VALUE
,	O
1	B-VALUE
retest	B-test
is	O
allowed	O
according	O
to	O
investigator	O
judgment	O
.	O

If	O
the	O
previous	O
investigational	O
product	O
has	O
a	O
long	O
half	O
-	O
life	O
,	O
3	O
months	O
or	O
5	O
half	O
-	O
lives	O
(	O
whichever	O
is	O
longer	O
)	O
should	O
have	O
passed	O
prior	O
to	O
screening	O

[	O
11	O
]	O
have	O
pustular	B-problem
,	I-problem
erythrodermic	I-problem
,	I-problem
and	I-problem
or	I-problem
guttate	I-problem
forms	I-problem
of	I-problem
psoriasis	I-problem
.	O

prior	O
to	O
baseline	O
belimumab	B-treatment
,	O
natalizumab	B-treatment
,	O
or	O
vedolizumab	B-treatment
within	B-TEMPORAL
6	I-TEMPORAL
months	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
B	B-treatment
-	I-treatment
celldepleting	I-treatment
agents	I-treatment
(	O
such	O
as	O
rituximab	B-treatment
)	O
or	O
other	B-treatment
cell	I-treatment
-	I-treatment
depleting	I-treatment
biologics	I-treatment
(	O
eg	O
,	O
anti	B-treatment
-	I-treatment
CD3	I-treatment
antibody	I-treatment
)	O
at	O
any	B-TEMPORAL
time	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL

[	O
36g	O
]	O
Serum	B-test
creatinine	I-test
>	B-VALUE
2	I-VALUE
.	I-VALUE
0	I-VALUE
mg	I-VALUE
dL	I-VALUE
.	O
Note	O

[	O
14	O
]	O
Have	O
received	O
systemic	B-treatment
nonbiologic	I-treatment
psoriasis	I-treatment
therapy	I-treatment
or	O
phototherapy	B-treatment
within	B-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
,	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
,	O
or	O
have	O
had	O
topical	B-treatment
psoriasis	I-treatment
treatment	I-treatment
within	B-TEMPORAL
2	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
,	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL
as	O
specified	O
in	O
Table	O
RHBQ	O
.	O
6	O
.	O
2	O
Exceptions	O
(	O
see	O
Table	O
RHBQ	O
.	O
6	O
.	O
2	O
)	O
mild	B-treatment
corticosteroids	I-treatment
will	O
be	O
permitted	O
for	O
use	O
limited	O
to	O
the	O
face	O
and	O
or	O
axilla	O

[	O
54	O
]	O
Have	O
evidence	O
of	O
active	B-problem
TB	I-problem
as	O
documented	O
by	O
a	O
positive	B-VALUE
purified	B-test
protein	I-test
derivative	I-test
(	I-test
PPD	I-test
)	I-test
test	I-test
(	O
5	B-VALUE
-	I-VALUE
mm	I-VALUE
induration	I-VALUE
between	O
approximately	O
2	B-TEMPORAL
and	I-TEMPORAL
3	I-TEMPORAL
days	I-TEMPORAL
after	I-TEMPORAL
application	I-TEMPORAL
,	O
regardless	O
of	O
vaccination	O
history	O
)	O
,	O
medical	O
history	O
,	O
clinical	O
symptoms	O
,	O
and	O
abnormal	B-VALUE
chest	B-test
x	I-test
-	I-test
ray	I-test
at	O
screening	O
.	O

Rescreening	O

For	O
male	O
subjects	O
with	O
female	O
partners	O
of	O
non	O
-	O
childbearing	O
potential	O
,	O
contraceptive	B-treatment
requirements	I-treatment
do	O
not	O
apply	O

[	O
1b	O
]	O
postmenopausal	O
female	O
subjects	O

Clinical	O
Pharmacology	O
Protocol	O

[	O
3	O
]	O
have	O
a	B-test
body	I-test
mass	I-test
index	I-test
(	I-test
BMI	I-test
)	I-test
of	O
18	B-VALUE
.	I-VALUE
0	I-VALUE
to	I-VALUE
32	I-VALUE
.	I-VALUE
0	I-VALUE
kg	I-VALUE
m2	I-VALUE
,	I-VALUE
inclusive	I-VALUE
,	O
at	B-TEMPORAL
time	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL

[	O
2	O
]	O
aged	O
21	O
to	O
65	O
years	O
(	O
inclusive	O
)	O
at	O
the	O
time	O
of	O
screening	O

[	O
32	O
]	O
are	O
currently	O
or	O
have	O
been	O
smokers	B-problem
or	O
users	B-problem
of	I-problem
tobacco	I-problem
or	O
nicotine	B-treatment
replacement	I-treatment
products	I-treatment
within	B-TEMPORAL
the	I-TEMPORAL
3	I-TEMPORAL
months	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
admission	I-TEMPORAL
and	O
or	O
have	O
positive	B-VALUE
cotinine	B-problem
at	O
screening	O
or	O
at	B-TEMPORAL
the	I-TEMPORAL
time	I-TEMPORAL
of	I-TEMPORAL
admission	I-TEMPORAL

If	O
the	B-test
QuantiFERON	I-test
-	I-test
TB	I-test
Gold	I-test
blood	I-test
test	I-test
is	O
available	O
and	O
certified	O
,	O
it	O
may	O
be	O
used	O
instead	O
of	O
the	B-test
PPD	I-test
skin	I-test
test	I-test
.	I-test

Patients	O
who	O
are	O
HBcAb	B-test
+	I-test
and	O
HBV	B-test
DNA	I-test
negative	B-VALUE
may	O
be	O
enrolled	O
in	O
the	O
study	O
.	O

[	O
9	O
]	O
are	O
investigator	O
site	O
personnel	O
directly	O
affiliated	O
with	O
this	O
study	O
or	O
are	O
members	O
of	O
their	O
immediate	O
families	O
.	O

[	O
28	O
]	O
are	O
currently	O
enrolled	O
in	O
a	O
clinical	O
trial	O
involving	O
an	O
investigational	O
product	O
or	O
nonapproved	O
use	O
of	O
a	O
drug	O
or	O
device	O
,	O
OR	O
are	O
concurrently	O
enrolled	O
in	O
any	O
other	O
type	O
of	O
medical	O
research	O
not	O
scientifically	O
or	O
medically	O
compatible	O
with	O
this	O
study	O
,	O
per	O
investigator	O
judgment	O

[	O
1	O
]	O
are	O
male	O
or	O
female	O
patients	O
18	O
years	O
or	O
older	O
.	O

[	O
1	O
]	O
Are	O
male	O
or	O
female	O
aged	O
between	O
18	O
and	O
65	O
years	O
(	O
inclusive	O
)	O
at	O
the	O
time	O
of	O
initial	O
screening	O
and	O
have	O
given	O
written	O
informed	O
consent	O
as	O
a	O
legal	O
adult	O
according	O
to	O
local	O
regulations	O
.	O

[	O
36	O
]	O
Had	O
any	B-treatment
major	I-treatment
surgery	I-treatment
within	B-TEMPORAL
8	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
first	I-TEMPORAL
admission	I-TEMPORAL
to	I-TEMPORAL
the	I-TEMPORAL
CRU	I-TEMPORAL
,	O
or	O
will	O
require	O
such	O
during	B-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
in	O
consultation	O
with	O
Lilly	O
or	O
its	O
designee	O
,	O
would	O
pose	O
an	O
unacceptable	O
risk	O
to	O
the	O
patient	O
.	O

Exclusion	O
Criteria	O

Individuals	O
may	O
be	O
rescreened	O
one	O
time	O
.	O

Subjects	O
taking	O
these	O
medications	O
should	O
be	O
on	O
chronic	O
,	O
stable	O
doses	O
.	O

Exceptions	O
include	O
patients	O
with	O
a	O
history	O
of	O
active	B-problem
or	I-problem
latent	I-problem
TB	I-problem
who	O
have	O
documented	O
evidence	O
of	O
appropriate	O
treatment	O
and	O
with	O
no	O
history	O
of	O
re	O
-	O
exposure	O
since	O
their	O
treatment	O
was	O
completed	O
.	O
(	O
Such	O
patients	O
would	O
not	O
be	O
required	O
to	O
undergo	O
the	O
protocol	O
specific	O
TB	O
testing	O
for	O
PPD	O
,	O
QuantiFERON	O
-	O
TB	O

In	O
locations	O
where	O
the	B-test
QuantiFERON	I-test
-	I-test
TB	I-test
Gold	I-test
blood	I-test
test	I-test
is	O
available	O
and	O
certified	O
,	O
it	O
may	O
be	O
used	O
instead	O
of	O
the	B-test
PPD	I-test
skin	I-test
test	I-test
.	I-test

Other	O
Exclusions	O

If	O
the	O
QuantiFERON	O
-	O
TB	O

[	O
56	O
]	O
Have	O
a	O
positive	B-VALUE
test	B-test
for	I-test
HBV	I-test
defined	O
as	O
a	O
.	O
positive	B-VALUE
for	O
hepatitis	B-test
B	I-test
surface	I-test
antigen	I-test
(	I-test
HBsAg	I-test
)	I-test
,	O
or	O
b	O
.	O
positive	B-VALUE
for	O
anti	B-test
-	I-test
hepatitis	I-test
B	I-test
core	I-test
antibody	I-test
(	I-test
HBcAb	I-test
)	I-test
but	O
negative	B-VALUE
for	O
hepatitis	B-test
B	I-test
surface	I-test
antibody	I-test
(	I-test
HBsAb	I-test
)	I-test
,	O
or	O
c	O
.	O
positive	B-VALUE
for	O
HBcAb	B-test
and	O
positive	B-VALUE
for	O
hepatitis	B-test
B	I-test
virus	I-test
deoxyribonucleic	I-test
acid	I-test
(	I-test
HBV	I-test
DNA	I-test
)	I-test

Medications	O
Therapies	O

Thus	O
,	O
each	O
barrier	O
method	O
must	O
include	O
use	O
of	O
a	O
spermicide	O
(	O
that	O
is	O
,	O
condom	B-treatment
with	I-treatment
spermicide	I-treatment
,	O
diaphragm	B-treatment
with	I-treatment
spermicide	I-treatment
,	O
female	B-treatment
condom	I-treatment
with	I-treatment
spermicide	I-treatment
)	O
.	O

Immediate	O
family	O
is	O
defined	O
as	O
a	O
spouse	O
,	O
parent	O
,	O
child	O
,	O
or	O
sibling	O
,	O
whether	O
biological	O
or	O
legally	O
adopted	O
.	O

[	O
9	O
]	O
are	O
investigative	O
site	O
personnel	O
directly	O
affiliated	O
with	O
this	O
study	O
and	O
their	O
immediate	O
families	O
.	O

Patients	O
who	O
meet	O
these	O
criteria	O
at	O
screening	O
will	O
be	O
identified	O
by	O
the	O
central	O
laboratory	O
and	O
monitored	O
during	O
the	O
study	O
as	O
detailed	O
in	O
Section	O
8	O
.	O
2	O
.	O
3	O
.	O
2	O
)	O
.	O

re	O
able	O
and	O
willing	O
to	O
give	O
signed	O
informed	O
consent	O

Investigators	O
should	O
review	O
the	O
vaccination	O
status	O
of	O
their	O
patients	O
and	O
follow	O
the	O
local	O
guidelines	O
for	O
adult	O
vaccination	O
with	O
nonlive	O
vaccines	O
intended	O
to	O
prevent	O
infectious	O
disease	O
prior	O
to	O
therapy	O
.	O
(	O
Note	O
Killed	O
inactive	O
vaccines	O
are	O
expected	O
to	O
be	O
safe	O
however	O
,	O
their	O
efficacy	O
with	O
concomitant	O
ixekizumab	O
treatment	O
has	O
not	O
been	O
confirmed	O
.	O
)	O

[	O
13	O
]	O
have	O
known	B-problem
allergies	I-problem
to	I-problem
LY3074828	I-problem
,	O
related	O
compounds	O
or	O
any	O
components	O
of	O
the	O
formulation	O
,	O
or	O
history	O
of	O
significant	B-problem
atopy	I-problem

Note	O
Patients	O
may	O
be	O
enrolled	O
if	O
they	O
have	O
had	O
a	O
history	O
of	O
inflammatory	B-problem
bowel	I-problem
disease	I-problem
(	I-problem
IBD	I-problem
)	I-problem
,	O
including	O
CD	B-problem
and	O
UC	B-problem
,	O
but	O
have	O
had	O
no	O
exacerbation	B-problem
for	O
6	B-TEMPORAL
months	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
randomization	O
and	O
,	O
if	O
currently	O
on	O
treatment	O
,	O
must	O
be	O
on	O
stable	B-treatment
treatment	I-treatment
for	O
6	B-TEMPORAL
months	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
randomization	O
.	O

If	O
the	B-test
test	I-test
results	O
are	O
positive	B-VALUE
,	O
the	O
patient	O
will	O
be	O
considered	O
to	O
have	O
latent	B-problem
TB	I-problem
and	O
will	O
be	O
excluded	O
.	O

[	O
31	O
]	O
are	O
immunocompromised	B-problem

[	O
15	O
]	O
Have	O
active	B-problem
fibromyalgia	I-problem
that	O
,	O
in	O
the	O
investigators	O
opinion	O
,	O
would	O
make	O
it	O
difficult	O
to	O
appropriately	O
assess	O
SLE	O
activity	O
for	O
the	O
purposes	O
of	O
this	O
study	O
.	O

When	O
rescreening	O
is	O
performed	O
,	O
the	O
individual	O
must	O
sign	O
a	O
new	O
ICF	O
and	O
will	O
be	O
assigned	O
a	O
new	O
identification	O
number	O
.	O

[	O
25	O
]	O
Have	O
uncontrolled	B-problem
arterial	I-problem
hypertension	I-problem
characterized	O
by	O
a	O
systolic	B-test
blood	I-test
pressure	I-test
(	I-test
BP	I-test
)	I-test
>	B-VALUE
160	I-VALUE
mm	I-VALUE
Hg	I-VALUE
or	O
diastolic	B-test
BP	I-test
>	B-VALUE
100	I-VALUE
mm	I-VALUE
Hg	I-VALUE
at	O
screening	O
(	O
Visit	O
1	O
)	O
or	O
baseline	O
randomization	O
(	O
Week	O
0	O

[	O
14	O
]	O
have	O
an	O
abnormality	B-VALUE
in	O
the	B-test
12	I-test
-	I-test
lead	I-test
ECG	I-test
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
increases	O
the	O
risks	O
associated	O
with	O
participating	O
in	O
the	O
study	O
.	O

Patients	O
are	O
eligible	O
to	O
be	O
included	O
in	O
the	O
study	O
only	O
if	O
they	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
at	O
screening	O
Type	O
of	O
Patient	O
and	O
Disease	O
Characteristics	O

LY2439821	O

TB	O
is	O
invalid	B-VALUE
or	O
borderline	B-VALUE
,	I-VALUE
1	B-VALUE
retest	B-test
is	O
allowed	O
according	O
to	O
investigator	O
judgment	O
.	O

re	O
able	O
to	O
read	O
and	O
understand	O
all	O
trial	O
-	O
related	O
material	O
and	O
complete	O
patient	O
-	O
reported	O
questionnaires	O
.	O

[	O
9	O
]	O
Had	O
a	B-problem
clinically	I-problem
significant	I-problem
flare	I-problem
of	I-problem
Ps	I-problem
during	B-TEMPORAL
the	I-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL

neutropenia	B-problem
(	O
absolute	B-test
neutrophil	I-test
count	I-test
<	B-VALUE
1000	I-VALUE
cells	I-VALUE
L	I-VALUE
[	I-VALUE
<	I-VALUE
1	I-VALUE
.	I-VALUE
00	I-VALUE
103	I-VALUE
L	I-VALUE
or	I-VALUE
<	I-VALUE
1	I-VALUE
.	I-VALUE
00	I-VALUE
GI	I-VALUE
L	I-VALUE
]	I-VALUE
)	O

[	O
9	O
]	O
are	O
Lilly	O
or	O
Covance	O
employees	O

A	O
single	B-VALUE
repeat	B-test
analysis	I-test
is	O
allowed	O
according	O
to	O
investigator	O
judgment	O
prior	O
to	O
making	O
a	O
final	O
determination	O
of	O
eligibility	O
.	O

[	O
22	O
]	O
are	O
unable	O
unwilling	O
to	O
stop	O
smoking	O
tobacco	O
products	O
while	O
in	O
the	O
study	O
unit	O
.	O

I8K	O
-	O
JE	O
-	O
JPDB	O
Clinical	O
Pharmacology	O
Protocol	O

ave	O
given	O
written	O
informed	O
consent	O
approved	O
by	O
Lilly	O
or	O
its	O
designee	O
and	O
by	O
the	O
ethical	O
review	O
board	O
(	O
ERB	O
)	O
institutional	O
review	O
board	O
(	O
IRB	O
)	O
governing	O
the	O
site	O
.	O

Immediate	O
family	O
is	O
defined	O
as	O
a	O
spouse	O
,	O
parent	O
,	O
child	O
,	O
or	O
sibling	O
,	O
whether	O
biological	O
or	O
legally	O
adopted	O
.	O

Subjects	O
are	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
only	O
if	O
they	O
meet	O
all	O
of	O
the	O
following	O
criteria	O
at	O
screening	O
and	O
or	O
enrollment	O

[	O
1a	O
]	O
male	O
subjects	O
agree	O
to	O
use	O
an	O
effective	O
method	O
of	O
contraception	B-treatment
(	O
barrier	B-treatment
contraceptives	I-treatment
,	O
such	O
as	O
latex	B-treatment
condoms	I-treatment
,	I-treatment
or	O
complete	O
abstinence	B-treatment
from	O
sexual	O
intercourse	O
with	O
women	O
)	O
for	O
the	O
duration	B-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
and	O
3	B-TEMPORAL
months	I-TEMPORAL
following	I-TEMPORAL
the	I-TEMPORAL
last	I-TEMPORAL
dose	I-TEMPORAL
of	I-TEMPORAL
IP	I-TEMPORAL

LY3009104	O
I4V	O
-	O
MC	O
-	O
JAHH	O

Exclusion	O
Criteria	O
5	O
.	O
2	O
.	O
1	O
.	O

[	O
8	O
]	O
are	O
investigative	O
site	O
personnel	O
directly	O
affiliated	O
with	O
this	O
study	O
and	O
their	O
immediate	O
families	O
.	O

[	O
45	O
]	O
Have	O
donated	O
more	B-VALUE
than	I-VALUE
a	I-VALUE
single	I-VALUE
unit	I-VALUE
of	O
blood	O
within	B-TEMPORAL
4	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
or	O
intend	O
to	O
donate	B-problem
blood	I-problem
during	B-TEMPORAL
the	I-TEMPORAL
course	I-TEMPORAL
of	I-TEMPORAL
the	I-TEMPORAL
study	I-TEMPORAL
.	O

[	O
23	O
]	O
have	O
used	O
or	O
intend	O
to	O
use	O
over	B-treatment
-	I-treatment
the	I-treatment
-	I-treatment
counter	I-treatment
or	I-treatment
prescription	I-treatment
medication	I-treatment
,	O
including	O
herbal	B-treatment
medications	I-treatment
,	O
within	B-TEMPORAL
14	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
dosing	I-TEMPORAL

Investigators	O
should	O
review	O
the	O
vaccination	O
status	O
of	O
their	O
subjects	O
and	O
follow	O
the	O
local	O
guidelines	O
for	O
vaccination	O
of	O
those	O
aged	O
18	O
years	O
with	O
nonlive	O
vaccines	O
intended	O
to	O
prevent	O
infectious	O
disease	O
before	O
entering	O
subjects	O
into	O
the	O
study	O
.	O

[	O
48	O
]	O

[	B-test
36b	I-test
]	I-test
Lymphocyte	I-test
count	I-test
<	B-VALUE
500	I-VALUE
cells	I-VALUE
L	I-VALUE
(	I-VALUE
<	I-VALUE
0	I-VALUE
.	I-VALUE
50	I-VALUE
103	I-VALUE
L	I-VALUE
or	I-VALUE
<	I-VALUE
0	I-VALUE
.	I-VALUE
50	I-VALUE
GI	I-VALUE
L	I-VALUE
)	I-VALUE

[	O
18	O
]	O
have	O
donated	B-problem
blood	I-problem
of	O
>	B-VALUE
500	I-VALUE
mL	I-VALUE
within	B-TEMPORAL
14	I-TEMPORAL
days	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
baseline	I-TEMPORAL

[	O
37	O
]	O
have	O
screening	B-test
electrocardiogram	I-test
(	I-test
ECG	I-test
)	I-test
abnormalities	B-VALUE
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
or	O
the	O
sponsor	O
,	O
are	O
clinically	O
significant	O
and	O
indicate	O
an	O
unacceptable	O
risk	O
for	O
the	O
patients	O
participation	O
in	O
the	O
study	O

[	O
9	O
]	O
Have	O
predominant	O
pattern	O
of	O
pustular	B-problem
,	I-problem
erythrodermic	I-problem
,	I-problem
and	I-problem
or	I-problem
guttate	I-problem
forms	I-problem
of	I-problem
Ps	I-problem
.	O

If	O
the	O
test	O
results	O
are	O
not	O
negative	O
,	O
the	O
patient	O
will	O
be	O
considered	O
to	O
have	O
latent	B-problem
TB	I-problem
(	O
for	O
purposes	O
of	O
this	O
study	O
)	O
or	O
o	O
QuantiFERON	B-test
-	I-test
TB	I-test
Gold	I-test
test	I-test
or	O
T	B-test
-	I-test
SPOT	I-test
.	I-test
TB	I-test
test	I-test
(	O
as	O
available	O
and	O
if	O
compliant	O
with	O
local	O
TB	O
guidelines	O
)	O
may	O
be	O
used	O
instead	O
of	O
the	O
PPD	O
test	O
.	O

[	O
34	O
]	O
Have	O
started	O
treatment	O
with	O
or	O
adjusted	O
the	O
dose	O
of	O
an	B-treatment
immunosuppressant	I-treatment
(	O
such	O
as	O
MTX	B-treatment
,	O
azathioprine	B-treatment
,	O
mycophenolate	B-treatment
)	O
within	B-TEMPORAL
10	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
screening	I-TEMPORAL
or	O
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
of	I-TEMPORAL
planned	I-TEMPORAL
randomization	I-TEMPORAL
.	O

re	O
able	O
and	O
have	O
given	O
written	O
informed	O
consent	O
approved	O
by	O
Lilly	O
,	O
or	O
its	O
designee	O
,	O
and	O
the	O
IRB	O
ERB	O
governing	O
the	O
site	O

a	O
negative	B-VALUE
TST	B-test
result	I-test
(	O
defined	O
as	O
a	O
skin	O
induration	O
<	O
5	O
mm	O
at	O
48	O
to	O
72	O
hours	O
after	O
administration	O
of	O
the	B-treatment
purified	I-treatment
protein	I-treatment
derivative	I-treatment
(	O
PPD	O
)	O
,	O
regardless	O
of	O
bacille	B-treatment
Calmette	I-treatment
-	I-treatment
Guerin	I-treatment
[	I-treatment
BCG	I-treatment
]	I-treatment
vaccine	I-treatment
or	O
other	B-treatment
vaccination	I-treatment
history	O
)	O
or	O
a	O
negative	B-VALUE
(	O
not	O
indeterminate	O
)	O
QuantiFERON	B-test
-	I-test
TB	I-test
Gold	I-test
Plus	I-test
test	I-test
(	O
QFTPlus	O
or	O
equivalent	O
)	O
.	O

[	O
6	O
]	O
meet	O
or	O
agree	O
to	O
abide	O
by	O
the	O
following	O

[	O
22	O
]	O
Have	O
had	O
symptomatic	B-problem
herpes	I-problem
zoster	I-problem
infection	I-problem
within	B-TEMPORAL
12	I-TEMPORAL
weeks	I-TEMPORAL
prior	I-TEMPORAL
to	I-TEMPORAL
screening	I-TEMPORAL
.	O

[	O
3	O
]	O
Have	O
10%	B-VALUE
BSA	B-test
involvement	I-test
at	O
screening	O
(	O
Visit	O
1	O
)	O
and	O
baseline	B-TEMPORAL
(	I-TEMPORAL
Week	I-TEMPORAL
0	I-TEMPORAL
Visit	I-TEMPORAL
2	I-TEMPORAL
)	I-TEMPORAL

before	O
screening	O
